Methods of treating chronic obstructive pulmonary disease in enhanced patient population using benralizumab

By using benarizumab combined with triple background therapy, the problem of poor treatment of eosinophil inflammation in COPD was solved, and the effect of reducing the rate of COPD worsening and improving lung function was achieved.

CN118949046APending Publication Date: 2024-11-15ASTRAZENECA AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411014628.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-05-16
Filing Date
2020-05-15
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat eosinophil inflammation in chronic obstructive pulmonary disease (COPD), especially with the problems of side effects of corticosteroids and poor treatment effects.

Method used

Using benarizumab, a monoclonal antibody specifically bound to eosinophils, induces eosinophil apoptosis through antibody-dependent cytotoxicity as a treatment for patients with enhanced COPD, combined with triple background Therapies include inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists.

Benefits of technology

Significantly reduce the annual deterioration rate of COPD, increase the one-second force exhalation volume (FEV1) and force vital capacity (FVC), improve the quality of life of patients, reduce the frequency of severe or very severe COPD, and have no side effects of corticosteroids.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949046A_ABST
    Figure CN118949046A_ABST
Patent Text Reader

Abstract

The present invention relates to methods of treating chronic obstructive pulmonary disease in an enhanced patient population using benralizumab. Provided herein are methods of treating chronic obstructive pulmonary disease (COPD) in a patient comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese patent application 202080035254.0, filed on May 15, 2020, "Methods for treating chronic obstructive pulmonary disease in enhanced patient populations using benralizumab."

[0002] Sequence Listing

[0003] This application contains a sequence listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy created on March 26, 2020 is named IL5R-607-WO-PCT_SL.txt and is 16,008 bytes in size. Technical Field

[0004] The present invention relates to the treatment of chronic obstructive pulmonary disease (COPD), and more particularly to a method for treating COPD in an enhanced patient population using benralizumab. Background Art

[0005] Chronic obstructive pulmonary disease (COPD) is the leading cause of morbidity and mortality in the world. Compared with other chronic diseases, COPD is increasingly common and is expected to be the third leading cause of death and disability in the world by 2020. The cost to society for treating COPD is high, accounting for about 3.4% of the total health care budget of the European Union. In the United States, the direct and indirect costs of COPD are estimated to be greater than $30 billion.

[0006] Approximately 30% of patients with COPD have elevated levels of eosinophils in the airways as measured by sputum induction or bronchoalveolar lavage. In COPD, the response to oral and inhaled corticosteroids (ICS) correlates with the intensity of airway eosinophilic inflammation, and a sputum eosinophil count greater than 3% has been demonstrated to be a good predictor of response to steroids in COPD.

[0007] The strategy of using increased corticosteroid therapy to control sputum eosinophilia greater than 3% in COPD leads to a reduction in the frequency of severe COPD exacerbations requiring hospitalization when patients gradually increase oral corticosteroid therapy. Standard treatment for acute exacerbations of COPD (AECOPD) includes the use of systemic corticosteroids to treat inflammation, which are associated with reduced hospital stays and accelerated recovery. Corticosteroids cause early apoptosis of eosinophils and generally reduce eosinophilia. However, long-term therapy with corticosteroids is associated with severe side effects such as suppression of the hypothalamus-pituitary-adrenal axis and osteoporosis, and corticosteroids are not all avoided in all eosinophilic COPD patients.

[0008] COPD patients with increased sputum eosinophil counts have been shown to have significant improvements in forced expiratory volume in one second (FEV1) and quality of life scores, which correlate with reduced sputum eosinophil counts and eosinophil cationic protein (ECP) levels. Therefore, therapies that specifically target eosinophils in COPD may have a beneficial effect.

[0009] Benralizumab is a humanized, afucosylated monoclonal antibody (mAb) that specifically binds to the α chain of human interleukin-5 receptor α (IL-5Rα) expressed on eosinophils. It induces apoptosis of these cells through antibody-dependent cellular cytotoxicity.

[0010] Therefore, given the high unmet need for treatment of COPD without corticosteroid-induced side effects, and given the fact that some patients with COPD have an eosinophilic component, the effect of benralizumab on COPD in adult subjects was examined. Summary of the invention

[0011] Provided herein are methods of treating chronic obstructive pulmonary disease (COPD) in a human COPD patient.

[0012] In certain aspects, described herein are methods of treating chronic obstructive pulmonary disease (COPD) in human COPD patients, the methods comprising administering a 100 mg dose of benralizumab or an antigen-binding fragment thereof to the COPD patient, wherein prior to administration, the patient: (a) has a blood eosinophil count ≥300 eosinophils / μL; (b) has experienced ≥2 prior exacerbations in the year prior to administration; and (c) is on triple background therapy comprising an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0013] In certain aspects, described herein are methods for reducing the annual exacerbation rate of COPD, the methods comprising administering a 100 mg dose of benralizumab or an antigen-binding fragment thereof to a human COPD patient, wherein prior to administration, the patient: (a) has a blood eosinophil count ≥300 eosinophils / μL; (b) has experienced ≥2 prior exacerbations in the year prior to administration; and (c) is on triple background therapy comprising an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA). In certain aspects, described herein are methods of reducing the annual exacerbation rate of severe or very severe COPD, the methods comprising administering a 100 mg dose of benralizumab or an antigen-binding fragment thereof to a human COPD patient, wherein prior to administration, the patient: (a) has a blood eosinophil count ≥300 eosinophils / μL; (b) has experienced ≥2 prior exacerbations in the year prior to administration; and (c) is on triple background therapy comprising an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0014] In certain aspects, described herein are methods of increasing forced expiratory volume in one second (FEV1) in human chronic obstructive pulmonary disease (COPD) patients, the methods comprising a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient: (a) has a blood eosinophil count ≥300 eosinophils / μL; (b) has experienced ≥2 prior exacerbations in the year prior to administration; and (c) is on triple background therapy comprising an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0015] In certain aspects, described herein are methods of increasing forced vital capacity (FVC) in human chronic obstructive pulmonary disease (COPD) patients, the methods comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient: (a) has a blood eosinophil count ≥300 eosinophils / μL; (b) has experienced ≥2 prior exacerbations in the year prior to administration; and (c) is on triple background therapy comprising an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0016] In some embodiments, the patient has a history of two or three or more exacerbations in the year prior to administration of benralizumab or an antigen-binding fragment thereof.

[0017] In some embodiments, patients receiving benralizumab are concurrently treated with triple background therapy, wherein the triple background therapy includes an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0018] In some embodiments, the patient receiving benralizumab is not concomitantly treated with triple background therapy, wherein the triple background therapy includes an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0019] In some embodiments, the patient has a blood eosinophil count of at least 300 eosinophils / μL before administration. In some embodiments, the patient has a blood eosinophil count of 300-450 eosinophils / μL before administration. In some aspects, the patient has a blood eosinophil count of greater than 400 eosinophils / μL before administration. In some aspects, the patient has a blood eosinophil count of greater than 450 eosinophils / μL before administration. In some aspects, the patient has a blood eosinophil count of greater than 500 eosinophils / μL before administration.

[0020] In some embodiments, the patient suffers from moderate, severe or very severe COPD as defined by the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). In some embodiments, the patient suffers from severe COPD as defined by GOLD. In other embodiments, the patient suffers from very severe COPD as defined by GOLD.

[0021] In some embodiments, administration reduces the exacerbation rate of COPD. In some embodiments, the exacerbation rate is reduced by at least 20% (e.g., at least 20%, at least 30%, at least 40%, at least 50%, or at least 60%). In some embodiments, the exacerbation rate is reduced within one year from the first administration of benralizumab or its antigen-binding fragment. In some embodiments, the exacerbation rate is reduced within six months from the first administration of benralizumab or its antigen-binding fragment.

[0022] In some embodiments, the patient has a post-bronchodilator FEV1 of ≤ 80% (eg, ≤ 70% or ≤ 65%) of predicted normal prior to administration of benralizumab or an antigen-binding fragment thereof.

[0023] In some embodiments, administration increases the patient's FEV1. In some aspects, the increased FEV1 is pre-bronchodilator FEV1. In some embodiments, pre-bronchodilator FEV1 increases by at least 10%. In some embodiments, pre-bronchodilator FEV1 increases by about 12%. In some embodiments, the increased FEV1 is post-bronchodilator FEV1. In some embodiments, post-bronchodilator FEV1 increases by at least 5%. In some aspects, post-bronchodilator FEV1 increases by about 7%. In some embodiments, pre-bronchodilator FEV1 and post-bronchodilator FEV1 increase. In some embodiments, FEV1 increases within one year from the first administration of benralizumab or its antigen-binding fragment.

[0024] In some embodiments, administration increases the patient's FVC. In certain aspects, the increased FVC is pre-bronchodilator FVC. In some embodiments, the increased FVC is post-bronchodilator FVC. In some embodiments, pre-bronchodilator FVC and post-bronchodilator FVC increase. In some embodiments, FVC increases by at least 3%. In some embodiments, FVC increases within one year from the first administration of benralizumab or its antigen-binding fragment.

[0025] In certain embodiments, administration improves the COPD questionnaire score assessing COPD symptoms. In some aspects, the COPD questionnaire is the St. George's Respiratory Questionnaire (SGRQ-C) specific to COPD. In some aspects, the SGRQ-C (symptom) score of the patient is reduced by at least 5. In some aspects, the SGRQ-C (symptom) score of the patient is reduced by at least 7.

[0026] In some embodiments, prior to administration of benralizumab or an antigen-binding fragment thereof, the patient's FEV1 / forced vital capacity (FVC) is <0.70.

[0027] In some embodiments, at least two doses of benralizumab or an antigen-binding fragment thereof are administered. In some embodiments, a first dose of benralizumab or an antigen-binding fragment thereof is administered on day 0, and a second dose is administered at 4 weeks. In some embodiments, at least one dose of benralizumab or an antigen-binding fragment thereof is administered at 8-week intervals after the previous dose. In some embodiments, benralizumab or an antigen-binding fragment thereof is administered at least one four-week dosing interval, followed by at least one eight-week dosing interval. In some embodiments, benralizumab or an antigen-binding fragment thereof is administered at three four-week dosing intervals, followed by eight-week dosing intervals.

[0028] In some embodiments, benralizumab or an antigen-binding fragment thereof is administered once every four weeks to once every twelve weeks. In some embodiments, benralizumab or an antigen-binding fragment thereof is administered once every four weeks. In some embodiments, benralizumab or an antigen-binding fragment thereof is administered once every eight weeks. In some embodiments, benralizumab or an antigen-binding fragment thereof is administered once every four weeks for twelve weeks and then administered once every eight weeks.

[0029] In some embodiments, the administration is subcutaneous administration.

[0030] In certain aspects, described herein are methods of treating chronic obstructive pulmonary disease (COPD) in a human COPD patient, the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient: (a) has a blood eosinophil count ≥300 eosinophils / μL; (b) has experienced ≥3 prior exacerbations in the year prior to administration; and (c) is on triple background therapy comprising an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0031] In certain aspects, described herein are methods of reducing the rate of chronic obstructive pulmonary disease (COPD) exacerbations in a human COPD patient, the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient: (a) has a blood eosinophil count ≥300 eosinophils / μL; (b) has experienced ≥3 prior exacerbations in the year prior to administration; and (c) is on triple background therapy comprising an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0032] In certain aspects, described herein are methods of increasing forced expiratory volume in one second (FEV1) in human chronic obstructive pulmonary disease (COPD) patients, the methods comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient: (a) has a blood eosinophil count ≥300 eosinophils / μL; (b) has experienced ≥3 prior exacerbations in the year prior to administration; and (c) is on triple background therapy comprising an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0033] In certain aspects, described herein are methods of increasing forced vital capacity (FVC) in human chronic obstructive pulmonary disease (COPD) patients, the methods comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient: (a) has a blood eosinophil count ≥300 eosinophils / μL; (b) has experienced ≥3 prior exacerbations in the year prior to administration; and (c) is on triple background therapy comprising an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0034] The present invention specifically relates to the following solutions:

[0035] 1. A method of treating chronic obstructive pulmonary disease (COPD) in a human COPD patient, the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient:

[0036] (a) blood eosinophil count ≥300 eosinophils / μL;

[0037] (b) experienced ≥2 prior exacerbations in the year prior to administration; and

[0038] (c) On triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0039] 2. A method for reducing the annual exacerbation rate of chronic obstructive pulmonary disease (COPD), the method comprising administering a 100 mg dose of benralizumab or an antigen-binding fragment thereof to a human COPD patient, wherein prior to administration, the patient:

[0040] (a) blood eosinophil count ≥300 eosinophils / μL;

[0041] (b) experienced ≥2 prior exacerbations in the year prior to administration; and

[0042] (c) On triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0043] 3. A method of increasing forced expiratory volume in one second (FEV1) in a human chronic obstructive pulmonary disease (COPD) patient, the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient:

[0044] (a) blood eosinophil count ≥300 eosinophils / μL;

[0045] (b) experienced ≥2 prior exacerbations in the year prior to administration; and

[0046] (c) On triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0047] 4. A method of increasing forced vital capacity (FVC) in a human chronic obstructive pulmonary disease (COPD) patient, the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient:

[0048] (a) blood eosinophil count ≥300 eosinophils / μL;

[0049] (b) experienced ≥2 prior exacerbations in the year prior to administration; and

[0050] (c) On triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0051] 5. The method of any one of schemes 1-4, wherein a COPD questionnaire score assessing COPD symptoms in the human COPD patient is improved.

[0052] 6. The method of any one of 1-5, wherein the patient suffers from severe or very severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

[0053] 7. The method of scheme 6, wherein the patient suffers from very severe COPD as defined by GOLD.

[0054] 8. The method of any one of schemes 1-7, wherein the administration reduces the exacerbation rate of COPD.

[0055] 9. The method of any one of schemes 2-8, wherein the exacerbation rate is reduced by at least 20%.

[0056] 10. The method of any one of schemes 2-8, wherein the exacerbation rate is reduced by at least 30%.

[0057] 11. The method of any one of schemes 2-8, wherein the exacerbation rate is reduced by at least 40%.

[0058] 12. The method of any one of schemes 2-8, wherein the exacerbation rate is reduced by at least 50%.

[0059] 13. The method of any one of schemes 2-8, wherein the exacerbation rate is reduced by at least 60%.

[0060] 14. The method of any one of schemes 1-13, wherein the administration increases the patient's FEV1.

[0061] 15. The method of any one of schemes 1-13, wherein the administration increases the patient's FVC.

[0062] 16. The method of claim 6, wherein the COPD questionnaire is a COPD-specific St. George's Respiratory Questionnaire (SGRQ-C).

[0063] 17. The method of claim 16, wherein the patient's SGRQ-C (symptom) score is reduced by at least 5.

[0064] 18. The method of any one of schemes 1-17, wherein the patient's SGRQ-C (symptom) score is reduced by at least 9.

[0065] 19. The method of any one of schemes 1-17, wherein the patient has experienced ≥ 3 prior exacerbations in the year prior to the administration.

[0066] 20. The method of any one of Schemes 1-19, wherein the patient receiving benralizumab is concurrently treated with triple background therapy, wherein the triple background therapy comprises an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0067] 21. The method of any one of Schemes 1-19, wherein the patient receiving benralizumab is not concurrently treated with triple background therapy, wherein the triple background therapy comprises an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0068] 22. The method of any one of schemes 1-21, wherein the patient has a FEV1 of ≤80% of predicted value prior to administration of benralizumab or an antigen-binding fragment thereof.

[0069] 23. The method of any one of schemes 1-21, wherein the patient has a FEV1 of ≤70% of predicted value prior to administration of benralizumab or an antigen-binding fragment thereof.

[0070] 24. The method of any one of schemes 1-21, wherein the patient has a FEV1 of ≤ 65% of predicted value prior to administration of benralizumab or an antigen-binding fragment thereof.

[0071] 25. The method of any one of schemes 1-21, wherein the patient has a FEV1 / forced vital capacity (FVC) of <0.70 prior to administration of benralizumab or an antigen-binding fragment thereof.

[0072] 26. The method of any one of schemes 1-25, wherein at least two doses of benralizumab or an antigen-binding fragment thereof are administered.

[0073] 27. The method of scheme 26, wherein benralizumab or an antigen-binding fragment thereof is administered once every four weeks to once every twelve weeks.

[0074] 28. The method of any one of schemes 1-26, wherein benralizumab or an antigen-binding fragment thereof is administered once every four weeks.

[0075] 29. The method of any one of schemes 1-26, wherein benralizumab or an antigen-binding fragment thereof is administered once every eight weeks.

[0076] 30. The method of any one of schemes 1-26, wherein benralizumab or an antigen-binding fragment thereof is administered once every four weeks for twelve weeks and then once every eight weeks.

[0077] 31. The method of any one of schemes 1-30, wherein the administration is subcutaneous administration.

[0078] 32. A method of treating chronic obstructive pulmonary disease (COPD) in a human COPD patient, the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient:

[0079] (a) blood eosinophil count ≥300 eosinophils / μl;

[0080] (b) experienced ≥3 prior exacerbations in the year prior to administration; and

[0081] (c) On triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0082] 33. A method of reducing the exacerbation rate of chronic obstructive pulmonary disease (COPD) in a human COPD patient, the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient:

[0083] (a) blood eosinophil count ≥300 eosinophils / μL;

[0084] (b) experienced ≥3 prior exacerbations in the year prior to administration; and

[0085] (c) On triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0086] 34. A method of increasing forced expiratory volume in one second (FEV1) in a human chronic obstructive pulmonary disease (COPD) patient, the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient:

[0087] (a) blood eosinophil count ≥300 eosinophils / μL;

[0088] (b) experienced ≥3 prior exacerbations in the year prior to administration; and

[0089] (c) On triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0090] 35. A method of increasing forced vital capacity (FVC) in a human chronic obstructive pulmonary disease (COPD) patient, the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient:

[0091] (a) blood eosinophil count ≥300 eosinophils / μL;

[0092] (b) experienced ≥3 prior exacerbations in the year prior to administration; and

[0093] (c) On triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0094] 36. The method of any one of schemes 32-25, wherein the patient receiving benralizumab is concurrently treated with triple background therapy, wherein the triple background therapy comprises an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0095] 37. The method of any one of schemes 32-35, wherein the patient receiving benralizumab is not concurrently treated with triple background therapy, wherein the triple background therapy comprises an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

[0096] 38. A method of treating chronic obstructive pulmonary disease (COPD) in a human COPD patient, the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to the first administration, the patient:

[0097] (a) blood eosinophil count ≥300 eosinophils / μL;

[0098] (b) experienced ≥2 prior exacerbations in the year prior to administration; and

[0099] (c) is on triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA); and wherein after administration of 100 mg of benralizumab once every four weeks for twelve weeks and then once every eight weeks, the patient is no longer on triple background therapy.

[0100] 39. A method of treating chronic obstructive pulmonary disease (COPD) in a human COPD patient, the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to the first administration, the patient:

[0101] (a) blood eosinophil count ≥300 eosinophils / μL;

[0102] (b) experienced ≥3 prior exacerbations in the year prior to administration; and

[0103] (c) is on triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA); and wherein after administration of 100 mg of benralizumab once every four weeks for twelve weeks and then once every eight weeks, the patient is no longer on triple background therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0104] Figure 1 A flow chart of the studies described in Examples 1 and 2 is shown.

[0105] Figure 2 A-2B is a graph showing the annual exacerbation rate (all = Figure 2 A and severe Figure 2 B) The data show that 100 mg benralizumab is more effective than 10 mg and 30 mg in reducing the annualized rate of COPD exacerbations and is particularly effective in reducing severe COPD exacerbations compared to the 10 mg and 30 mg doses.

[0106] Figure 3 A-3B shows GALATHEA ( Figure 3 A) and TERRANOVA( Figure 3 B) Graph of changes from baseline in lung function (FEV1) and SGRQ scores of 100 mg and 30 mg. The data overall showed that benralizumab 100 mg showed a better treatment effect in improving lung function (FEV1) and SGRQ scores compared to the 10 mg and 30 mg doses.

[0107] Figure 4 A-4B is shown in GALATHEA ( Figure 4 A) and TERRANOVA( Figure 4 In B), the median blood eosinophil count changes over time during treatment with benralizumab for patients with baseline blood eosinophil count ≥220 / μL.

[0108] Figure 5 A-5B is a graph showing that in patients with a baseline blood eosinophil count ≥ 220 / μL, the TERRANOVA was performed by prior exacerbation ( Figure 5 A) and through background therapy ( Figure 5 B) Graph of the annual COPD exacerbation rate ratios for patients receiving 100 mg benralizumab analyzed. TERRANOVA showed that the annual exacerbation rate (AER) was reduced by 23% for patients with ≥3 exacerbations in the year prior to administration, compared to a 2% reduction for patients with ≤2 exacerbations in the year prior to administration. TERRANOVA also showed that the AER was reduced by 17% for patients receiving triple inhaled therapy, compared to a 7% reduction in the AER for the overall population.

[0109] Figure 6 A-6B is a table showing that in patients with baseline blood eosinophil counts ≥220 / μL, GALATHEA was associated with a decrease in the number of eosinophils in patients with a baseline blood eosinophil count of ≥220 / μL. Figure 6 A) and through background therapy ( Figure 6 B) Graph of the Annualized COPD Exacerbation Rate Ratio for patients receiving 100 mg of benralizumab analyzed. GALATHEA showed a 39% reduction in the Annualized Exacerbation Rate (AER) for patients with ≥3 exacerbations in the year prior to dosing compared to placebo, compared to a 2% reduction for patients with ≤2 exacerbations in the year prior to dosing and an 18% reduction in the AER for patients receiving triple inhaled therapy.

[0110] Figure 7 A-7B shows GALATHEA ( Figure 7 A) and TERRANOVA( Figure 7 B) Annualized COPD exacerbation rate ratios analyzed by baseline blood eosinophil level. Using only the stratification criterion, there was no clear trend between increasing baseline blood eosinophil count and treatment effect.

[0111] Figure 8 A-8D shows the annualized total exacerbation rate (ERR) and severe exacerbation rate (severe ERR) for GALATHEA and TERRANOVA in patients with ≥300 eosinophils / μL and on triple background therapy (ICS / LABA / LAMA) analyzed by prior exacerbation in the year prior to dosing: ERR for patients with ≤2 exacerbations ( Figure 8 A); severe ERR in patients with ≤2 exacerbations ( Figure 8 B); ERR in patients with ≥3 exacerbations ( Figure 8 C); and severe ERR in patients with ≥3 exacerbations ( Figure 8 D). The data showed that patients with ≥300 eosinophils / μL, ongoing triple background therapy (ICS / LABA / LAMA) and ≤2 exacerbations in the year prior to administration experienced a benefit from benralizumab therapy. Patients with ≥300 eosinophils / μL, ongoing triple background therapy (ICS / LABA / LAMA) and ≥3 exacerbations in the year prior to administration experienced the greatest treatment effect of benralizumab, especially at a dose of 100 mg.

[0112] Fig. 9 A-9D shows that in patients with a baseline eosinophil count ≥220 / μL, GALATHEA ( Fig. 9 A, 9C) and TERRANOVA( Fig. 9 B, 9D) by respiratory disease characteristics analysis of annual COPD exacerbation rate ratio. Data show

[0113] Fig.10 A-10B shows the effect of benralizumab compared with placebo on the annualized exacerbation rate (AER) in moderate / severe and severe patients.

[0114] Fig.11 A flow chart of the study described in Example 3 is shown. DETAILED DESCRIPTION

[0115] The present disclosure describes new study populations identified based on findings from GALATHEA and TERRANOVA, which were previous Phase 3 studies of benralizumab in patients with moderate to very severe COPD, as described in Examples 1 and 2. Subgroup analyses of GALATHEA and TERRANOVA consistently identified patients with a history of more frequent exacerbations and those receiving triple background therapy as most likely to respond to treatment with benralizumab 100 mg. Specifically, the subgroup analyses yielded the following results:

[0116] - A >30% reduction in the annualized severe COPD exacerbation rate with benralizumab 100 mg compared to placebo.

[0117] - In both studies, patients on triple (ICS / LABA / LAMA) background therapy (approximately 70% and 60% of patients in GALATHEA and TERRANOVA, respectively) had consistent treatment effects on annualized COPD exacerbation rate with benralizumab 100 mg. At benralizumab 100 mg, GALATHEA showed an 18% reduction in AER compared to placebo in patients on triple background therapy. At benralizumab 100 mg, TERRANOVA showed a 17% reduction in AER in patients on triple background therapy compared to a 7% reduction in AER for the overall population.

[0118] - With benralizumab 100 mg, patients with more frequent exacerbations (≥3 vs ≤2) in the year prior to benralizumab administration had better treatment effects on the annual exacerbation rate of COPD and the annual exacerbation rate of severe COPD. However, patients with ≤2 exacerbations in the year prior to administration still experienced benefit from benralizumab therapy.

[0119] -No treatment effect on the annualized rate of COPD exacerbations was observed in patients with baseline blood eosinophils <220 / μL.

[0120] Findings in these subgroups were consistent across studies and supported by pooled analyses. Taken together, these characteristics identify those patients most likely to benefit from benralizumab treatment.

[0121] It should be noted that the term "a or an" entity refers to one or more of the entity; for example, "anti-IL-5α antibody" should be understood to mean one or more anti-IL-5α antibodies. Therefore, the terms "a or an", "one or more", and "at least one" are used interchangeably herein.

[0122] Provided herein are methods for treating chronic obstructive pulmonary disease (COPD). The provided methods include administering an effective amount of benralizumab or an antigen-binding fragment thereof.

[0123] Information about benralizumab (or its fragment) used in the methods provided herein can be found, for example, in U.S. Patent Application Publication No. US2010 / 0291073 A1, the disclosure of which is incorporated herein by reference in its entirety. Benralizumab and its antigen-binding fragment used in the methods provided herein include heavy chains and light chains or heavy chain variable regions and light chain variable regions. In another aspect, benralizumab or its antigen-binding fragment used in the methods provided herein include any one of the amino acid sequences of SEQ ID NO:1-4. In a specific aspect, benralizumab or its antigen-binding fragment used in the methods provided herein include a light chain variable region comprising an amino acid sequence of SEQ ID NO:1 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:3. In a specific aspect, benralizumab or its antigen-binding fragment used in the methods provided herein include a light chain comprising an amino acid sequence of SEQ ID NO:2 and a heavy chain comprising an amino acid sequence of SEQ ID NO:4. In a specific aspect, benralizumab or its antigen-binding fragment used in the method provided herein includes a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region includes the Kabat-defined CDR1, CDR2, and CDR3 sequences of SEQ ID NO:7-9, and wherein the light chain variable region includes the Kabat-defined CDR1, CDR2, and CDR3 sequences of SEQ ID NO:10-12. One of ordinary skill in the art will be able to easily identify the CDR defined by Chothia, the CDR defined by Abm, or other CDRs. In a specific aspect, benralizumab or its antigen-binding fragment used in the method provided herein includes the variable heavy chain and variable light chain CDR sequences of the KM1259 antibody as disclosed in US6,018,032, which reference is incorporated herein by reference in its entirety.

[0124] An acute exacerbation of COPD (AECOPD) is a sustained worsening of the patient's condition from a stable state and beyond normal daily variation, which is acute in onset and necessitates a change in the patient's conventional medication therapy for the underlying COPD.

[0125] In some aspects, benralizumab or its Fab is applied to the patient with COPD who appears in the physician's office or emergency room (ED). In view of benralizumab can reduce or deplete eosinophil counts for up to 12 weeks or longer (see US 2010 / 0291073), benralizumab or its Fab can be applied only once or infrequently, and still provide benefits for the patient. In other aspects, the patient is applied with other subsequent doses. Depending on the patient's age, weight, ability to cooperate with physician instructions, clinical assessment, eosinophil counts (blood or sputum eosinophils or eosinophil cationic protein (ECP) measured values) or other factors (including the judgment of the attending physician), subsequent doses can be applied at different time intervals. The time interval between dosage can be every 4 weeks, every 5 weeks, every 6 weeks, every 8 weeks, every 10 weeks, every 12 weeks or longer time interval. In some aspects, the interval between dosage can be every 4 weeks or every 8 weeks. In some aspects, the intervals between doses can be every 4 weeks and every 8 weeks. In some aspects, benralizumab or its antigen-binding fragment is administered at three four-week dosing intervals (i.e., at day 0, week 4, and week 8), followed by eight-week dosing intervals (i.e., at week 16, week 24, week 32, etc.). In some aspects, benralizumab or its antigen-binding fragment is administered once every 4 weeks for 12 weeks. In some aspects, benralizumab or its antigen-binding fragment is administered once every 4 weeks for 12 weeks, followed by one administration every 8 weeks.

[0126] In certain aspects, a single dose or a first dose is administered to a COPD patient shortly after the patient presents with an acute exacerbation (e.g., mild, moderate, and severe exacerbations). For example, a single or first dose of benralizumab or an antigen-binding fragment thereof can be administered during a clinic or hospital visit, or in the case of a very severe exacerbation, within 1, 2, 3, 4, 5, 6, 7 or more days, such as 7 days, of the acute exacerbation, allowing the patient's symptoms to stabilize prior to administration of benralizumab.

[0127] In some embodiments, at least two doses of benralizumab or an antigen-binding fragment thereof are administered to the patient. In some embodiments, at least three doses, at least four doses, at least five doses, at least six doses, or at least seven doses are administered to the patient. In some embodiments, benralizumab or an antigen-binding fragment thereof is administered over the course of four weeks, over the course of eight weeks, over the course of twelve weeks, over the course of twenty-four weeks, over the course of forty-eight weeks, or over the course of one year or more.

[0128] The amount of benralizumab or its antigen-binding fragment to be administered to a patient can depend on various parameters, such as the patient's age, weight, clinical assessment, eosinophil count (blood or sputum eosinophils, eosinophil cationic protein (ECP) measurements, or eosinophil-derived neurotoxins (EDN) measurements), or other factors (including the judgment of the attending physician). In certain aspects, the dose or dose interval does not depend on the eosinophil level.

[0129] In certain aspects, the patient is administered one or more doses of benralizumab or an antigen-binding fragment thereof, wherein the dose is about 100 mg.

[0130] In certain aspects, administration of benralizumab or its antigen-binding fragment according to the methods provided herein can be by parenteral administration. For example, benralizumab or its antigen-binding fragment can be administered by intravenous infusion or by subcutaneous injection. In certain embodiments, benralizumab or its antigen-binding fragment can be administered by subcutaneous injection.

[0131] In some aspects, benralizumab or its Fab is combined or combined with other therapies according to the method provided herein.Such therapies include but are not limited to corticosteroid therapy (including inhaled corticosteroids (ICS)), long-acting beta agonists (LABA, including long-acting beta 2 agonists), long-acting muscarinic antagonists (LAMA, including tiotropium bromide) or other standard therapies.In some aspects, benralizumab or its Fab is combined or combined with ICS and LABA, LABA and LAMA or ICS, LABA and LAMA according to the method provided herein.In some aspects, the term "triple background therapy" means ICS, LABA and LAMA.

[0132] In certain instances, administration of benralizumab or an antigen-binding fragment thereof reduces COPD exacerbations, including those measured, for example, by exacerbation rate, annual exacerbation rate, time to first exacerbation, and / or annual COPD exacerbation rate associated with emergency department visits or hospitalizations.

[0133] The method provided herein can reduce the exacerbation rate in COPD patients. In some aspects, compared with the number of exacerbations expected according to the patient's medical history, compared with the average number of exacerbations expected in comparable patient populations, or compared with comparable populations treated with placebo in the same time period, using the method provided herein, that is, the number of exacerbations experienced by the patient is reduced by administering benralizumab or its antigen-binding fragment. In some aspects, the administration of benralizumab or its antigen-binding fragment reduces the number of exacerbations in COPD patients, and the COPD patients have at least 300 eosinophils / μL of eosinophil counts before administration. In some aspects, the administration of benralizumab or its antigen-binding fragment reduces the number of exacerbations in COPD patients, and the COPD patients have at least 400 eosinophils / μL of eosinophil counts before administration. In some aspects, the administration of benralizumab or its antigen-binding fragment reduces the number of exacerbations in COPD patients, and the COPD patients suffer from severe COPD as defined by the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD), GOLD is a global strategy for diagnosing, managing and preventing chronic obstructive pulmonary disease (revised in 2018). In some aspects, the administration of benralizumab or its antigen-binding fragment reduces the number of exacerbations in COPD patients, and the COPD patients suffer from very severe COPD as defined by GOLD. In some aspects, the administration of benralizumab or its antigen-binding fragment reduces the number of exacerbations in COPD patients, and the COPD patients suffer from severe or very severe COPD as defined by GOLD. In some aspects, the administration of benralizumab or its antigen-binding fragment reduces the number of exacerbations in COPD patients, and the COPD patients are receiving corticosteroids (e.g., inhaled corticosteroids (ICS)), long-acting beta agonists (LABA) (e.g., long-acting beta 2 agonists) and long-acting muscarinic antagonists (LAMA) (e.g., tiotropium bromide).

[0134] In certain aspects, the administration of benralizumab or its antigen-binding fragment reduces the number of COPD exacerbations (e.g., reduces the annual exacerbation rate) of patients who have experienced ≥2 previous exacerbations in the year prior to administration. In certain aspects, the administration of benralizumab or its antigen-binding fragment reduces the number of COPD exacerbations (e.g., reduces the annual exacerbation rate) of patients who have experienced ≥3 previous exacerbations in the year prior to administration. In certain aspects, the administration of benralizumab or its antigen-binding fragment reduces the number of severe COPD exacerbations (e.g., reduces the annual severe exacerbation rate) of patients who have experienced ≥3 previous exacerbations in the year prior to administration.

[0135] In certain aspects, administration of benralizumab or an antigen-binding fragment thereof reduces the number of exacerbations of COPD (e.g., reduces the annual exacerbation rate) in patients who exhibit the following characteristics prior to administration: a) a blood eosinophil count ≥300 eosinophils / μL; b) have experienced ≥2 prior exacerbations in the year prior to administration; and c) are on triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA) (e.g., a long-acting beta2 agonist), and a long-acting muscarinic antagonist (LAMA) (e.g., tiotropium bromide). In certain aspects, administration of benralizumab or an antigen-binding fragment thereof reduces the number of exacerbations of COPD (e.g., reduces the annual exacerbation rate) in patients who exhibit the following characteristics prior to administration: a) a blood eosinophil count ≥300 eosinophils / μL; b) have experienced ≥3 prior exacerbations in the year prior to administration; and c) are on triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA) (e.g., a long-acting beta2 agonist), and a long-acting muscarinic antagonist (LAMA) (e.g., tiotropium bromide).

[0136] In certain aspects, administration of benralizumab or an antigen-binding fragment thereof treats chronic obstructive pulmonary disease (COPD) in a patient who exhibits the following characteristics prior to administration: (a) a blood eosinophil count ≥300 eosinophils / μL; (b) has experienced ≥3 prior exacerbations in the year prior to administration; and (c) is on triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA); wherein following administration of 100 mg of benralizumab once every four weeks for twelve weeks and then once every eight weeks, the patient is no longer on triple background therapy. In certain aspects, administration of benralizumab or an antigen-binding fragment thereof treats chronic obstructive pulmonary disease (COPD) in a patient who exhibits the following characteristics prior to administration: (a) a blood eosinophil count ≥300 eosinophils / μL; (b) has experienced ≥2 prior exacerbations in the year prior to administration; and (c) is on triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LAMA); wherein following administration of 100 mg of benralizumab once every four weeks for twelve weeks and then once every eight weeks, the patient is no longer on triple background therapy,

[0137] In certain aspects, the administration of benralizumab or its antigen-binding fragment reduces exacerbations by at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 55%, or at least about 60%. In some embodiments, exacerbations are reduced by about 17%, or about 18%. In some embodiments, the administration of benralizumab or its antigen-binding fragment reduces severe exacerbations by at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 55%, or at least about 60%. In some embodiments, severe exacerbations are reduced by about 32%, or about 43%. Exacerbations (moderate or severe) can be reduced, for example, within one year from the first administration of benralizumab or its antigen-binding fragment. In one aspect, exacerbations (moderate or severe) can be reduced within 6 months from the first administration of benralizumab or an antigen-binding fragment thereof.

[0138] In certain aspects, using the methods provided herein, i.e., administering benralizumab or an antigen-binding fragment thereof, reduces the exacerbation rate (e.g., reduces the annual exacerbation rate) of COPD (e.g., moderate or severe) within 4 weeks, within 8 weeks, within 12 weeks, within 16 weeks, within 20 weeks, within 24 weeks, within 28 weeks, within 32 weeks, within 36 weeks, within 40 weeks, within 44 weeks, within 48 weeks, or within 52 weeks.

[0139] The methods provided herein can also reduce the exacerbation rate (e.g., reduce the annual exacerbation rate) of COPD (e.g., moderate or severe) in patients with an eosinophil count ≥ 300 eosinophils / μL prior to administration, such as by at least 20%, at least 30%, at least 50%, or at least 60%.

[0140] The methods provided herein can also reduce exacerbation rate (e.g., reduce annual exacerbation rate) in COPD patients with severe or very severe COPD (as defined by GOLD), such as by at least 40%, at least 50%, at least 60%, or at least 70%.

[0141] As used herein, the terms "annual exacerbation rates," "annualized exacerbation rate," "rate of exacerbation," or "rate of annual exacerbation" are used interchangeably. The methods provided herein can reduce the "annual exacerbation rate" in moderate to very severe COPD patients. In assessing the annual COPD exacerbation rate, a COPD exacerbation is defined as a worsening of the symptoms of COPD that requires:

[0142] Use of systemic corticosteroids for at least 3 days (a single depot injection of corticosteroids is considered equivalent to a 3-day course of systemic corticosteroids); and / or

[0143] Use of antibiotics; and / or

[0144] Hospitalization of inpatients due to COPD.

[0145] The methods provided herein can reduce the time to first COPD exacerbation after a first administration of benralizumab or an antigen-binding fragment thereof compared to after a first administration of a placebo.

[0146] In some examples, administration of benralizumab or an antigen-binding fragment thereof reduces the likelihood of a COPD exacerbation (e.g., within 52 weeks of the first administration of benralizumab or an antigen-binding fragment thereof) compared to the likelihood of a COPD exacerbation following treatment with a placebo.

[0147] In some instances, administration of benralizumab or an antigen-binding fragment thereof reduces the annualized rate of COPD exacerbations associated with emergency room visits or hospitalizations compared to administration of a placebo.

[0148] In certain instances, administration of benralizumab or an antigen-binding fragment thereof improves lung function in COPD patients, for example as measured by forced expiratory volume in one second (FEV1) or forced vital capacity.

[0149] The method provided herein can increase the forced expiratory volume in one second (FEV1) in COPD patients. The increase can be measured based on the expected FEV1, which is based on a large patient population, based on the FEV1 measured in a control population, or based on the FEV1 of a single patient before administration. In some aspects, compared with the baseline FEV1 of the patient, the method provided herein, i.e., the administration of benralizumab or its antigen-binding fragment can increase FEV1. In some embodiments, the increased FEV1 is the pre-bronchodilator FEV1. In some embodiments, the increased FEV1 is the post-bronchodilator FEV1. In some embodiments, the increased FEV1 is the pre-bronchodilator FEV1 and the post-bronchodilator FEV1. FEV1 (e.g., pre-bronchodilator and / or post-bronchodilator FEV1) can, for example, increase within one year from the first administration of benralizumab or its antigen-binding fragment.

[0150] As used herein, "bronchodilator" refers to any drug that widens or dilates the bronchi and bronchioles or airways of the lungs, reduces resistance in the respiratory airways, and / or eases breathing by relaxing bronchial smooth muscle. For example, bronchodilators include short-acting and long-acting beta 2 agonists such as salbutamol and other drugs commonly used to treat asthma.

[0151] In some embodiments, the patient has a post-bronchodilator FEV1 of ≤ 80% (eg, ≤ 70% or ≤ 65%) of predicted normal prior to administration of benralizumab or an antigen-binding fragment thereof.

[0152] In some aspects, the methods provided herein can increase FEV1 by at least 5% or at least 10%. In some aspects, the methods provided herein can increase FEV1 by about 12%. In some aspects, the methods provided herein can increase pre-bronchodilator FEV1 by at least 5% or at least 10%. In some aspects, the methods provided herein can increase pre-bronchodilator FEV1 by about 12%.

[0153] In some aspects, the methods provided herein can increase FEV1 by at least 5%. In some aspects, the methods provided herein can increase FEV1 by about 7%. In some aspects, the methods provided herein can increase post-bronchodilator FEV1 by at least 5%. In some aspects, the methods provided herein can increase post-bronchodilator FEV1 by about 7%.

[0154] In some aspects, the method provided herein can increase the pre-bronchodilator FEV1 and post-bronchodilator FEV1 by at least 5%. In some aspects, the method provided herein can increase the pre-bronchodilator FEV1 by at least 10% and increase the post-bronchodilator FEV1 by at least 5%. In some aspects, the method provided herein can increase the pre-bronchodilator FEV1 by about 12% and increase the post-bronchodilator FEV1 by about 7%.

[0155] As provided herein, administration of benralizumab or an antigen-binding fragment thereof can also increase the predicted FEV1 percentage in COPD patients, e.g., before and / or after bronchodilators. For example, the predicted FEV1 percentage can be increased by about 3.0, about 3.5, about 4.0, or about 4.5.

[0156] The methods provided herein can increase FEV1 in COPD patients with a blood eosinophil count of at least 300 eosinophils / μL, and / or in patients receiving corticosteroids (e.g., inhaled corticosteroids (ICS)), long-acting beta agonists (LABAs) (e.g., long-acting beta2 agonists), and long-acting muscarinic antagonists (e.g., tiotropium), and / or in patients who have experienced ≥2 or ≥3 prior exacerbations in the year prior to administration. In certain aspects, the methods provided herein can increase FEV1 in COPD patients who: a) have a blood eosinophil count of at least 300 eosinophils / μL, b) receive corticosteroids (e.g., inhaled corticosteroids (ICS)), long-acting beta agonists (LABAs) (e.g., long-acting beta2 agonists), and long-acting muscarinic antagonists (e.g., tiotropium), and c) have experienced ≥2 prior exacerbations in the year prior to administration. In certain aspects, the methods provided herein can increase the FEV1 of COPD patients: a) having a blood eosinophil count of at least 300 eosinophils / μL, b) receiving corticosteroids (e.g., inhaled corticosteroids (ICS)), long-acting beta agonists (LABA) (e.g., long-acting beta 2 agonists) and long-acting muscarinic antagonists (e.g., tiotropium bromide), and c) experiencing ≥3 previous exacerbations in the year before administration. In certain aspects, the methods provided herein can increase the FEV1 in such patients by at least 10% or at least 15%. In certain aspects, the methods provided herein can increase the pre-bronchodilator FEV1 in such patients by at least 10% or at least 15%. In certain aspects, the methods provided herein can increase the post-bronchodilator FEV1 in such patients by about 10%. In certain aspects, the methods provided herein can increase the pre-bronchodilator FEV1 and post-bronchodilator FEV1 in such patients by at least 10%. In certain aspects, the methods provided herein can increase pre-bronchodilator FEV1 in such patients by at least 15% and increase post-bronchodilator FEV1 in such patients by at least 10%.

[0157] The method provided herein can increase FEV1 in COPD patients with blood eosinophil counts of at least 300 eosinophils / μL or in COPD patients suffering from severe or very severe COPD as defined by the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). In some aspects, the method provided herein can increase the FEV1 in such patients by at least 15% or at least 20%. In some aspects, the method provided herein can increase the pre-bronchodilator FEV1 in such patients by at least 15% or at least 20%. In some aspects, the method provided herein can increase the post-bronchodilator FEV1 in such patients by about 15%. In some aspects, the method provided herein can increase the pre-bronchodilator FEV1 and post-bronchodilator FEV1 in such patients by at least 15%. In some aspects, the method provided herein can increase the pre-bronchodilator FEV1 in such patients by at least 20% and increase the post-bronchodilator FEV1 in such patients by at least 15%. In some aspects, the method provided herein can increase the pre-bronchodilator FEV1 in such patients by at least 20% and increase the post-bronchodilator FEV1 in such patients by at least 15%.

[0158] In certain aspects, using the methods provided herein, i.e., administering benralizumab or an antigen-binding fragment thereof, increases FEV1 within 4 weeks, within 8 weeks, within 12 weeks, within 16 weeks, within 20 weeks, within 24 weeks, within 28 weeks, within 32 weeks, within 36 weeks, within 40 weeks, within 44 weeks, within 48 weeks, within 52 weeks, or within 56 weeks or longer. In certain aspects, administration of benralizumab or an antigen-binding fragment thereof improves FEV1 within 52 weeks of the first administration of benralizumab or an antigen-binding fragment thereof. Use of the methods provided herein can increase FEV1 by at least 0.05 L, at least 0.1 L, at least 0.13 L, at least 0.15 L, at least 0.20 L, at least 0.21 L, at least 0.22 L, at least 0.23 L, at least 0.24 L, or at least 0.25 L, at least 0.30 L, at least 0.35 L, at least 0.40 L, at least 0.45 L, or at least 0.50 L over a 56 week period.

[0159] The method provided herein can increase the forced vital capacity (FVC) in COPD patients. Increase can be measured based on expected FVC, and the expected FVC is based on a large patient population, based on the FVC measured in a control population, or based on the FVC of a single patient before administration. In some aspects, compared with the baseline FVC of the patient, the method provided herein is used, that is, FVC can be increased by administering benralizumab or its Fab. In certain embodiments, the increased FVC is FVC before bronchodilator. In certain embodiments, the increased FVC is FVC after bronchodilator. In certain embodiments, the increased FVC is FVC before bronchodilator and FVC after bronchodilator. FVC (e.g., FVC before bronchodilator and / or FVC after bronchodilator) can, for example, increase within one year from the first administration of benralizumab or its Fab.

[0160] In some aspects, the method provided herein can increase FVC by at least 3%. In some aspects, the method provided herein can increase FVC before bronchodilator by at least 2%, at least 3%, at least 5% or at least 10%. In some aspects, the method provided herein can increase FVC after bronchodilator by at least 2%, at least 3%, at least 5% or at least 10%. In some aspects, the method provided herein can increase FVC before bronchodilator and FVC after bronchodilator by at least 2%, at least 3%, at least 5% or at least 10%. In some aspects, the method provided herein can increase FVC before bronchodilator and FVC after bronchodilator by at least 2%, at least 3%, at least 5% or at least 10%. In some aspects, using the method provided herein, that is, applying benralizumab or its antigen-binding fragment within 4 weeks, within 8 weeks, within 12 weeks, within 16 weeks, within 20 weeks, within 24 weeks, within 28 weeks, within 32 weeks, within 36 weeks, within 40 weeks, within 44 weeks, within 48 weeks, within 52 weeks, or within 56 weeks or longer to increase FVC.

[0161] In certain instances, administration of benralizumab or an antigen-binding fragment thereof improves respiratory symptoms in COPD patients, such as measured by the Basal / Transitional Dyspnea Index (BDI / TDI) and / or the Chronic Lung Disease Exacerbation Tool-Respiratory Symptoms (E-RS).

[0162] Also provided herein are methods for improving respiratory symptoms as measured by the basal / transitional dyspnea index (TDI). For example, administration of benralizumab or an antigen-binding fragment thereof can improve (increase) the BDI score of a COPD patient by at least 1, at least 2, or at least 3 and / or produce a positive TDI score. The BDI / TDI score can, for example, improve within one year from the first administration of benralizumab or an antigen-binding fragment thereof.

[0163] In certain aspects, use of the methods provided herein, i.e., administration of benralizumab or an antigen-binding fragment thereof, improves BDI / TDI scores within 4 weeks, within 8 weeks, within 12 weeks, within 16 weeks, within 20 weeks, within 24 weeks, within 28 weeks, within 32 weeks, within 36 weeks, within 40 weeks, within 44 weeks, within 48 weeks, within 52 weeks, or within 56 weeks or longer.

[0164] Also provided herein are methods for improving respiratory symptoms as measured by the Chronic Lung Disease Exacerbation Tool - Respiratory Symptoms (E-RS). For example, administration of benralizumab or an antigen-binding fragment thereof can improve (reduce) the E-RS score of a COPD patient by at least 3, at least 4, at least 6, at least 7, at least 8, at least 9, or at least 10. The E-RS score can be improved, for example, within one year from the first administration of benralizumab or an antigen-binding fragment thereof.

[0165] In certain aspects, use of the methods provided herein, i.e., administration of benralizumab or an antigen-binding fragment thereof, improves E-RS scores within 4 weeks, within 8 weeks, within 12 weeks, within 16 weeks, within 20 weeks, within 24 weeks, within 28 weeks, within 32 weeks, within 36 weeks, within 40 weeks, within 44 weeks, within 48 weeks, within 52 weeks, or within 56 weeks or longer.

[0166] In certain examples, administration of benralizumab or an antigen-binding fragment thereof improves health status and / or health-related quality of life in COPD patients, e.g., as measured by the St. George's Respiratory Questionnaire (SGRQ), the COPD-specific St. George's Respiratory Questionnaire (SGRQ-C), and / or the COPD Assessment Tool (CAT).

[0167] Provided herein are methods for improving COPD symptoms, for example, as assessed using a COPD questionnaire such as the St. George's Respiratory Questionnaire (SGRQ). For example, administration of benralizumab or an antigen-binding fragment thereof can improve the patient's SGRQ score by at least 2, at least 3, at least 4, at least 6, at least 7, at least 8, at least 9, or at least 10. The SGRQ score can improve, for example, within one year from the first administration of benralizumab or an antigen-binding fragment thereof.

[0168] In certain aspects, using the methods provided herein, i.e., administration of benralizumab or an antigen-binding fragment thereof improves SGRQ scores within 4 weeks, within 8 weeks, within 12 weeks, within 16 weeks, within 20 weeks, within 24 weeks, within 28 weeks, within 32 weeks, within 36 weeks, within 40 weeks, within 44 weeks, within 48 weeks, within 52 weeks, or within 56 weeks or longer. In certain aspects, administration of benralizumab or an antigen-binding fragment thereof improves SGRQ scores within 52 weeks of the first administration of benralizumab or an antigen-binding fragment thereof.

[0169] Also provided herein are methods for improving COPD symptoms, for example, as assessed using a COPD questionnaire such as the COPD-specific St. George's Respiratory Questionnaire (SGRQ-C). For example, administration of benralizumab or an antigen-binding fragment thereof can improve the SGRQ-C (symptom) score of a COPD patient by at least 2, at least 3, at least 4, at least 6, at least 7, at least 8, at least 9, or at least 10. The SGRQ-C (symptom) score can improve, for example, within one year from the first administration of benralizumab or an antigen-binding fragment thereof.

[0170] In certain aspects, use of the methods provided herein, i.e., administration of benralizumab or an antigen-binding fragment thereof, improves SGRQ-C (symptom) scores within 4 weeks, within 8 weeks, within 12 weeks, within 16 weeks, within 20 weeks, within 24 weeks, within 28 weeks, within 32 weeks, within 36 weeks, within 40 weeks, within 44 weeks, within 48 weeks, within 52 weeks, or within 56 weeks or longer.

[0171] Also provided herein are methods for improving COPD symptoms, for example, as assessed using the COPD Assessment Tool (CAT). For example, administration of benralizumab or an antigen-binding fragment thereof can improve (reduce) the CAT score of a COPD patient by at least 2, at least 3, at least 4, at least 6, at least 7, at least 8, at least 9, or at least 10. The CAT score can, for example, improve (reduce) within one year from the first administration of benralizumab or an antigen-binding fragment thereof.

[0172] In certain aspects, use of the methods provided herein, i.e., administration of benralizumab or an antigen-binding fragment thereof, improves (reduces) CAT scores within 4 weeks, within 8 weeks, within 12 weeks, within 16 weeks, within 20 weeks, within 24 weeks, within 28 weeks, within 32 weeks, within 36 weeks, within 40 weeks, within 44 weeks, within 48 weeks, within 52 weeks, or within 56 weeks or longer.

[0173] In certain aspects, use of the methods provided herein, i.e., administration of benralizumab or an antigen-binding fragment thereof, reduces nighttime awakenings.

[0174] In certain aspects, use of the methods provided herein, i.e., administration of benralizumab or an antigen-binding fragment thereof, reduces the use of rescue medication.

[0175] In certain aspects, use of the methods provided herein, ie, administration of benralizumab or an antigen-binding fragment thereof, reduces the severity, frequency, and / or duration of an EXACT-PRO defined event.

[0176] In certain aspects, use of the methods provided herein, ie, administration of benralizumab or an antigen-binding fragment thereof, reduces the annual rate of hospitalization due to COPD.

[0177] In certain aspects, use of the methods provided herein, ie, administration of benralizumab or an antigen-binding fragment thereof, reduces annual hospitalizations and annual emergency department visits due to COPD.

[0178] In certain aspects, use of the methods provided herein, i.e., administration of benralizumab or an antigen-binding fragment thereof, reduces the annual rate of unplanned outpatient visits due to COPD.

[0179] In certain aspects, use of the methods provided herein, ie, administration of benralizumab or an antigen-binding fragment thereof, reduces the annual rate of unplanned healthcare visits due to COPD.

[0180] In certain aspects, using the methods provided herein, i.e., administering benralizumab or an antigen-binding fragment thereof reduces COPD-specific resource utilization. For example, administration of benralizumab or an antigen-binding fragment thereof can reduce unplanned physician visits, unscheduled calls to physicians, and / or use of other COPD medications.

[0181] In certain aspects, use of the methods provided herein, i.e., administration of benralizumab or an antigen-binding fragment thereof, reduces the annualized severe COPD exacerbation rate, wherein severe COPD exacerbations are defined by worsening symptoms of COPD requiring inpatient hospitalization or leading to death from COPD.

[0182] In certain aspects, the methods provided herein are used, i.e., administering benralizumab or an antigen-binding fragment thereof to a COPD patient increases forced expiratory volume in one second (FEV1), increases forced vital capacity (FVC), reduces COPD exacerbation rate, and / or improves COPD questionnaire scores (e.g., COPD Control Questionnaire).

[0183] In certain aspects, using the methods provided herein, administering benralizumab or an antigen-binding fragment thereof to COPD patients reduces the annual COPD exacerbation rate, improves SGRQ scores, and increases FEV1 (e.g., in COPD patients with a baseline blood eosinophil count ≥300 cells / μL).

[0184] In certain aspects, prior to administration of benralizumab or its antigen-binding fragment, COPD patients are prescribed or have used corticosteroids (e.g., inhaled corticosteroids (ICS)), long-acting beta agonists (LABA, e.g., long-acting beta2 agonists) and long-acting muscarinic antagonists (LAMA). In certain aspects, ICS, LABA and LAMA are used simultaneously with benralizumab or its antigen-binding fragment to treat COPD patients. In certain aspects, ICS, LABA and LAMA and benralizumab or its antigen-binding fragment are not used simultaneously to treat COPD patients.

[0185] In some aspects of the method provided herein, the patient has a history of COPD exacerbation. In some aspects, the history of exacerbation is included in at least two exacerbations in one year before the use of benralizumab or its Fab. In some aspects, the history of exacerbation is included in at least three exacerbations in one year before the use of benralizumab or its Fab. In some aspects, the patient has a forced expiratory volume (FEV1) less than 80% predicted value before use. In some aspects, the patient has a FEV1 / FVC less than 0.70 before use.

[0186] In some aspects, for example, before applying benralizumab or its antigen-binding fragment, COPD patients have specific blood eosinophil counts. For example, blood eosinophil counts can be measured using a complete blood count (CBC) with cell classification. In some aspects, before applying benralizumab or its antigen-binding fragment, COPD patients have blood eosinophil counts of ≥300 eosinophils / μL. In some aspects, before applying benralizumab or its antigen-binding fragment, the patient has a blood eosinophil count of 300-450 eosinophils / μL. In some aspects, before applying benralizumab or its antigen-binding fragment, the patient has a blood eosinophil count greater than 400 eosinophils / μL. In some aspects, before applying benralizumab or its antigen-binding fragment, the patient has a blood eosinophil count greater than 450 eosinophils / μL.

[0187] In some aspects, COPD patients have moderate COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), i.e., GOLD II. In some aspects, COPD patients have severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), i.e., GOLD III. In some aspects, COPD patients have very severe COPD as defined by GOLD, i.e., GOLD IV. In some aspects, COPD patients have severe or very severe COPD as defined by GOLD, i.e., GOLD III or IV.

[0188] Examples

[0189] Example 1: Patients and Methods

[0190] GALATHEA and TERRANOVA are Phase III supplemental studies designed to evaluate the efficacy (based on a reduction in the annualized moderate to severe exacerbation rate) and safety of benralizumab in patients with moderate to very severe COPD who are at risk for exacerbations and have a blood eosinophil count ≥220 / μL (a threshold that predicts the selection of patients who may respond to benralizumab based on previous results). The following examples report the primary results of GALATHEA and TERRANOVA.

[0191] Experimental design

[0192] GALATHEA (NCT02138916) and TERRANOVA (NCT02155660) are phase III, randomized, double-blind, placebo-controlled, parallel-group trials. Each trial included an enrollment visit, a 3-week screening period, a 56-week randomized treatment period, and a follow-up visit ( Figure 1 ).

[0193] Eligible patients were stratified according to country and blood eosinophil count (≥300 / μL and <300 / μL). Enrollment was capped primarily for groups with baseline eosinophil counts <220 / μL, 220-299 / μL, and ≥300 / μL to maintain a predetermined group size and a ratio of approximately 2:1 of patients with eosinophil counts ≥220 / μL (primary analysis population) to patients with <220 / μL. This design enriched the trial population with patients who may respond to benralizumab (blood eosinophil counts ≥220 / μL) and allowed the assessment of the benefit: risk ratio of benralizumab in COPD patients with a range of blood eosinophil counts. Dose selection was based on the approved asthma doses of 30mg, 100mg to inform safety margins and the 10mg asthma dose to assess dose-efficacy relationships.

[0194] At randomization, eligible patients were assigned in a ratio of 1:1:1 or 1:1:1:1 to receive placebo or benralizumab (30 mg or 100 mg in GALATHEA; 10 mg, 30 mg, or 100 mg in TERRANOVA), respectively. Complete eligibility criteria are provided in the trial protocol (available at NEJM.org). Study medication was administered by subcutaneous injection every 4 weeks for the first three doses and every 8 weeks thereafter. During the study, patients' maintenance and rescue medication use was recorded daily via an electronic diary (eDiary). Eligibility for randomization included ≥70% compliance (based on eDiary) with the prescribed inhaled maintenance therapy during the run-in period.

[0195] The primary population for all analyses included patients with a baseline blood eosinophil count ≥220 / μL. The primary endpoint for both trials was the annualized COPD exacerbation rate at week 56. Key secondary endpoints included change from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1) and St. George's Respiratory Questionnaire (SGRQ) scores. Safety endpoints included the type and frequency of adverse events (AEs).

[0196] A COPD exacerbation was defined as a worsening of COPD symptoms that resulted in the use of oral corticosteroids for ≥3 days and / or the use of antibiotics and / or COPD-related hospitalization or death (see the Supplementary Appendix). Respiratory symptoms were recorded daily in eDiary and assessed at central visits. Patients completed the SGRQ during central visits. Additional assessments that were used but not reported included the COPD Assessment Test, the Baseline / Transitional Dyspnea Index, the Chronic Lung Disease Exacerbation Tool-Patient-Reported Outcomes, and the EuroQOL 5D 5L. Spirometry data and safety data were collected at central visits, but the results were read centrally (see the Supplementary Appendix).

[0197] Study Procedure

[0198] Data were collected from all patients during the following periods:

[0199] - Enrollment (week -4)

[0200] -Every 2 weeks during the run-in / screening period (week -3 to week -1)

[0201] -During randomization (week 0) and induction period (week 2)

[0202] - Every 4 weeks during the reduction and maintenance phase (week 4-week 56)

[0203] - Follow-up (week 60)

[0204] Spirometry

[0205] Patients underwent pre-bronchodilator spirometry at enrollment, at Visit 2 (Week 3) during the Run-in / Screening Period, and at Weeks -3, 0, 4, 8, 16, 24, 32, 40, 48, and 56 during the Treatment Period. Patients underwent post-bronchodilator spirometry at Visit 2 (Week -3), and a subset of patients also underwent post-bronchodilator spirometry at enrollment, at Weeks -3, 0, 4, 8, 16, 24, 32, 40, 48, and 56. Spirometry was performed by the investigator or authorized representative according to the American Thoracic Society / European Respiratory Society guidelines.

[0206] COPD Assessment Tests

[0207] COPD Assessment Test (CAT) is developed to measure eight patient-reported outcomes (PRO) tools for the impact of COPD on health status. The tool uses a semantically distinct six-point answer scale, which is defined by contrasting adjectives to capture the impact of COPD. Content includes projects related to cough, phlegm, chest tightness, shortness of breath when climbing / stairs, limited activities at home, confidence in leaving home, sleep, and energy. The CAT total score is the sum of project answers. Score is in the range of 0-40, and wherein higher scores indicate that COPD has a greater impact on health status. Patients complete CAT tests when visiting the following research centers: Visit 4 (week 0), Visit 6 (week 4), Visit 7 (week 8), Visit 9 (week 16), Visit 11 (week 24), Visit 13 (week 32), Visit 15 (week 40), Visit 17 (week 48) and Visit 19 (week 56).

[0208] Evaluation of COPD exacerbations

[0209] A COPD exacerbation is defined as a change in a patient's usual COPD symptoms that lasts for 2 or more days, is beyond the normal daily variation, is acute in onset and may require a change in usual medications, and results in any of the following:

[0210] - Use of systemic corticosteroids for at least 3 days

[0211] - A single depot injection dose of corticosteroids is considered equivalent to a 3-day course of systemic corticosteroids

[0212] -Use of antibiotics

[0213] -Inpatient hospitalization due to COPD (defined as an inpatient admission for ≥24 hours in a hospital, observation area, emergency department, or other equivalent health care facility, depending on the country and healthcare system)

[0214] If COPD exacerbation requires treatment with systemic steroids and / or antibiotics and does not result in hospitalization or death, the COPD exacerbation is considered to be moderate. If the exacerbation results in hospitalization or death, the exacerbation is considered to be severe. Patients evaluate symptoms via eDiary every morning for the purpose of symptom aggravation alarms. The purpose of this alarm is to simultaneously notify patients and research centers of potential symptom exacerbation events that require contact between patients and research centers for further evaluation. Every morning, patients complete three questions about the main symptoms of aggravation events (dyspnea, sputum volume, and sputum color). One or more of these symptoms reported by patients trigger an assessment of the secondary symptoms of aggravation events (sore throat, cold, fever without other causes, cough and wheezing). There are three answer options for questions about the severity of symptoms and their usual state (e.g., how was your shortness of breath level in the past 24 hours? Shortness of breath level lower than usual, usual shortness of breath level, more shortness of breath than usual). Questions related to whether there are symptoms have two-point answers (e.g., have you had a sore throat in the past 24 hours? No, yes, I have had a sore throat).

[0215] The eDiary system generates an alert to the patient and site if at least two major symptoms or one major and one minor symptom worsen for 2 consecutive days. If the event is not related to the eDiary symptom exacerbation alert as described above (e.g., technical issues, patient self-reported symptom exacerbation / worsening events, exacerbations identified during visits or phone calls, exacerbations evaluated and treated at a non-site location, or acute / severe symptom exacerbations not captured by the ePRO system), the investigator will meet with the patient and assess the potential worsening and duration of the following symptoms: shortness of breath, mucus volume, mucus purulent discharge, cough, wheezing, sore throat, cold symptoms such as runny or stuffy nose, fever, and chest tightness.

[0216] The onset of an exacerbation was defined as the date of initiation of systemic corticosteroid or antibiotic therapy or hospital admission, whichever occurred earlier, and the end date was defined as the last day of systemic corticosteroid or antibiotic therapy or hospital discharge, whichever occurred later. COPD exacerbations that occurred within ≤7 days of the last dose of systemic steroids (oral, intramuscular, intravenous) or antibiotics or the last day of hospitalization were counted as the same exacerbation event.

[0217] Assessment of blood eosinophils

[0218] Patients were stratified according to the absolute blood eosinophil count assessed by the central laboratory (hematology samples were drawn at Visit 1 [Week -4]). Randomization was capped at the study level of the baseline eosinophil cohort (<220 / μL, 220-299 / μL, ≥300 / μL) to maintain the predefined cohort sample size and an approximately 2:1 ratio of patients above to below the 220 / μL cutoff. Once any eosinophil cohort was filled, patients assigned to that specific cohort based on the Visit 1 eosinophil count were screened as ineligible.

[0219] Security

[0220] An independent data monitoring committee evaluated cumulative safety and other clinical trial data. Major adverse cardiac events and malignancies were assessed by an independent trial committee.

[0221] Research Recipe

[0222] For the first three doses, 20 mg / mL, 30 mg / mL or 100 mg / mL benralizumab injection solution (corresponding to 10 mg, 30 mg and 100 mg) in a prefilled syringe with accessories was administered by subcutaneous injection at the research center every 4 weeks, and then every 8 weeks, and the last dose of benralizumab was administered at week 48. According to the same schedule as benralizumab, a matching placebo injection solution in a prefilled syringe with accessories was administered by subcutaneous injection at the research center. Each study patient received two syringes, filled with 1 mL and 0.5 mL, respectively, and blinding was achieved in a double-dummy manner.

[0223] Clinical evaluation

[0224] COPD Assessment Test: The COPD Assessment Test (CAT) is an eight-item patient-reported outcome (PRO) tool developed to measure the impact of COPD on health status. The tool uses a semantically distinct six-point answer scale, which is defined by contrasting adjectives to capture the impact of COPD. The content includes items related to cough, phlegm, chest tightness, shortness of breath when climbing / stairs, limited activities at home, confidence in leaving home, sleep, and energy. The CAT total score is the sum of the project answers. The score is in the range of 0-40, where a higher score indicates that COPD has a greater impact on health status. Patients complete the CAT test when visiting the following research centers: Visit 4 (week 0), Visit 6 (week 4), Visit 7 (week 8), Visit 9 (week 16), Visit 11 (week 24), Visit 13 (week 32), Visit 15 (week 40), Visit 17 (week 48) and Visit 19 (week 56).

[0225] St. George's Respiratory Questionnaire: The St. George's Respiratory Questionnaire (SGRQ) is a 50-item PRO tool developed to measure the health status of patients with obstructive airway disease. The questionnaire is divided into two parts: Part 1 consists of eight items about the severity of respiratory symptoms in the previous 4 weeks; Part 2 consists of 42 items related to the daily activity and psychosocial impact of individual respiratory conditions. The SGRQ produces a total score and three domain scores (symptoms, activity, and impact). The total score indicates the impact of the disease on overall health status. This total score is expressed as a percentage of total impairment, with 100 indicating the worst possible health status and 0 indicating the best possible health status. Similarly, domain scores range from 0-100, with higher scores indicating greater impairment. The developers provide specific details of the SGRQ scoring algorithm in the user manual. 2 Patients completed the SGRQ at the following study center visits: Visit 4 (Week 0), Visit 6 (Week 4), Visit 7 (Week 8), Visit 9 (Week 16), Visit 11 (Week 24), Visit 13 (Week 32), Visit 15 (Week 40), Visit 17 (Week 48), and Visit 19 (Week 56).

[0226] Base / Transitional Dyspnea Index: The Base / Transitional Dyspnea Index (BDI / TDI) is a tool developed to provide a multidimensional measure of dyspnea associated with activities of daily living. The BDI provides a measure of dyspnea at a single state baseline, and the TDI evaluates changes in dyspnea from a baseline state. The tool consists of the following three components: functional impairment, task magnitude, and workload as assessed by the 5-level scale of the BDI and the 7-level scale of the TDI. Patients completed the BDI at visit 4 (week 0) at the study center. Patients completed the TDI at the following study center visits: visit 6 (week 4), visit 7 (week 8), visit 9 (week 16), visit 11 (week 24), visit 13 (week 32), visit 15 (week 40), visit 17 (week 48), and visit 19 (week 56).

[0227] Modified Medical Research Council Dyspnea Scale: The mMRC Dyspnea Scale assesses a patient's level of dyspnea using a simple grading system consisting of five statements about perceived shortness of breath. It is an interviewer-administered ordinal scale on which patients rate their dyspnea according to five levels of increasing severity. The mMRC Dyspnea Scale was completed at site visit 4 (week 0).

[0228] Chronic Lung Disease Exacerbation Tool - Patient Reported Outcomes: EXACT-PRO / E-RS COPD is a 14-item PRO tool developed to assess the frequency, severity, and duration of COPD exacerbations. The tool was developed for daily home management via a handheld electronic device. Respondents were instructed to complete a diary just before going to bed each night and answer questions while thinking about their "today" experiences. Scores range from 0-100, with higher scores indicating severity. Patients complete EXACT-PRO / E-RS COPD at home every night.

[0229] EuroQOL 5D 5L: The EuroQOL 5D 5L assesses the following 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension has five response options (no problem, slight problem, moderate problem, severe problem, and extreme problem) that reflect increasing levels of difficulty. Patients complete the EuroQOL 5D 5L weekly (±2 days) at home.

[0230] Safety Assessment

[0231] Baseline data from a complete physical examination were collected at Visit 1. Any new findings or exacerbations of existing findings were reported as adverse events. In addition to the physical examination, the following were recorded at each visit: smoking status, anthropometric measurements, and vital signs. A 12-lead electrocardiogram (ECG) was also performed in the supine position after the participant rested for at least 5 minutes. The ECG was performed between interventions.

[0232] Laboratory safety assessments of clinical chemistry, hematology, and urinalysis were also performed. Clinical chemistry profiles included the following: alkaline phosphatase, ALT, AST, blood urea nitrogen, calcium, chloride, carbon dioxide, creatinine, gamma-glutamyl transpeptidase, glucose, phosphorus, sodium, total bilirubin, total cholesterol, and uric acid.

[0233] Hematologic analysis included hematocrit, hemoglobin, mean corpuscular volume, platelet count, red blood cell count, and white blood cell differential count.

[0234] Urinalysis includes the following: appearance, blood, color, glucose, ketones, microscopic examination of white and red blood cells, pH, and specific gravity.

[0235] Statistical analysis

[0236] In the primary analysis, the number of COPD exacerbations observed in patients during the 56 weeks of double-blind treatment was used as the response variable.

[0237] Annual deterioration rate = number of deteriorations * 365.25 / (last follow-up date - visit 4 date + 1).

[0238] Via the negative binomial model, the exacerbation rate in each benralizumab dose group was compared with the exacerbation rate in the placebo group. The model included treatment group, eosinophil group (220-299 / μL or ≥300 / μL), country, background therapy (ICS / LABA, LABA / LAMA or ICS / LABA / LAMA) and the covariate of the number of exacerbations in the year before the study. The logarithm of the follow-up time was used as the displacement variable in the model.

[0239] All secondary efficacy endpoints of patients with baseline blood eosinophil counts ≥220 / μL were analyzed. Repeated measures analysis was performed on patients with baseline pre-dose / pre-bronchodilator FEV1 and at least one pre-randomized pre-dose / pre-bronchodilator FEV1 in the full analysis set, and the changes of pre-dose / pre-bronchodilator FEV1 relative to baseline at week 56 were compared between each of the three benralizumab dose groups and placebo. The dependent variable was the change of pre-bronchodilator FEV1 relative to baseline at the post-baseline protocol-specified visit (until the end-of-treatment visit). The treatment group was fitted as an explanatory variable, and the eosinophil group (220-299 / μL or ≥300 / μL), country, background therapy (ICS / LABA, LABA / LAMA or ICS / LABA / LAMA), visit, interaction between visit and treatment, and baseline pre-bronchodilator FEV1 were fitted as covariates. The visit was fitted as a categorical variable, and the variance-covariance matrix was assumed to be unstructured. The model is:

[0240] Change in FEV1 = treatment group + eosinophil group (220-299 / μL or ≥300 / μL) + baseline FEV1 + country + background therapy (ICS / LABA, LABA / LAMA, or ICS / LABA / LAMA) + visit + treatment*visit

[0241] Changes from baseline at Week 56 in the SGRQ total score and three domain scores (symptoms, activity, and impact) were analyzed separately by models similar to those used above for change from baseline in pre-dose / pre-bronchodilator FEV1.

[0242] Sensitivity analyses of the primary and key secondary end points based on different assumptions about the mechanism of missing data (including those that were expected to be more conservative, such as missing not at random) were used to explore the robustness of any treatment effects, including multiple imputation approaches.

[0243] To account for the multiplicity of testing the primary endpoint (exacerbation rate) and two key secondary endpoints (FEV1 and SGRQ) in each of the 30 mg and 100 mg dose groups (for patients with baseline blood eosinophil count ≥220 / μL), the following testing strategy was used to control the overall type I error rate at the 0.05 level:

[0244] Step 1: Perform two tests of annualized COPD exacerbation rate (one test for each dose versus placebo) via the Hochberg procedure at a familywise error rate (FWER) of 0.04. If both p-values ​​are < 0.04, proceed to Step 2; if the smaller p-value is < 0.02, proceed to Step 2a. Otherwise, do not exclude the null hypothesis.

[0245] Step 2: The two key secondary endpoints at both doses were tested as a family via the Holm procedure at a FWER of 0.05.

[0246] Step 2a: Two secondary endpoints at smaller P-value doses were tested via the Holm procedure with a FWER of 0.01.

[0247] Secondary End Points

[0248] Improvements in SGRQ scores were reported in both studies; however, overall improvements in SGRQ scores were reported for patients in the placebo group and across all treatment groups (least squares mean change from baseline, GALATHEA, placebo [-3.86] vs. 10 mg [0.00] vs. 30 mg [-4.87] vs. 100 mg [-5.99], and TERRANOVA, placebo [-6.50] vs. 10 mg [-7.51] vs. 30 mg [-7.89] vs. 100 mg [-7.10] ( Figure 3 ).

[0249] patient

[0250] GALATHEA and TERRANOVA included patients aged 40-85 years with 1) moderate to very severe COPD (screening post-bronchodilator FEV1 / forced vital capacity <0.70 and post-bronchodilator FEV1>20% and ≤65% of predicted normal); 2) cumulative or past smoking exposure ≥10 pack-years; 3) symptoms (modified Medical Research Council Dyspnea Scale score ≥1 at screening); and 4) a history of ≥2 moderate COPD exacerbations requiring treatment with oral corticosteroids and / or antibiotics or ≥1 COPD exacerbation requiring hospitalization in the year prior to enrollment despite treatment with dual therapy (ICS / LABA or LABA / LAMA) or triple therapy (ICS / LABA / LAMA) in the previous year. Patients were excluded if they had a primary diagnosis of asthma (prior history of asthma [e.g., in childhood or adolescence] was allowed).

[0251] Exclusion criteria

[0252] Patients were not included in the study if any of the following exclusion criteria were met:

[0253] - Clinically important lung disease other than COPD (e.g., active lung infection, clinically significant bronchiectasis, pulmonary fibrosis, cystic fibrosis, obesity-related hypoventilation syndrome, lung cancer, alpha-1 antitrypsin deficiency, and primary ciliary dyskinesia), or another diagnosed lung disease or systemic disease associated with an elevated peripheral eosinophil count (e.g., allergic bronchopulmonary aspergillosis / fungal disease, allergic granulomatous vasculitis, hypereosinophilic syndrome), and / or radiologic findings suggestive of a respiratory disease other than COPD contributing to the patient's respiratory symptoms;

[0254] - Any disorder that the investigator deems unstable, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematologic, psychiatric, or serious physical injury, and / or the disorder may:

[0255] - Affects the safety of patients throughout the study;

[0256] - affect the research findings or their interpretation; or

[0257] - Impedes the patient's ability to complete the study duration.

[0258] - Treatment with systemic corticosteroids and / or antibiotics and / or hospitalization for COPD exacerbation within 2 weeks prior to enrollment (Visit 1) or during the enrollment and screening / run-in periods, based on the last dose of steroids or last date of hospitalization, whichever occurred later.

[0259] - Acute upper or lower respiratory tract infection within 2 weeks prior to enrollment (Visit 1) or during enrollment and screening / run-in periods.

[0260] - Pneumonia within 8 weeks prior to enrollment (Visit 1) or during the enrollment and screening / run-in periods based on the last day of antibiotic treatment or hospitalization date, whichever occurred later.

[0261] Statistical analysis

[0262] Regarding sample size calculations, the primary endpoint required an estimated 348 patients per treatment group with baseline blood eosinophil count ≥220 / μL (overall total patients: GALATHEA, 1,044; TERRANOVA, 1,392) to provide 90% power to detect a 30% reduction in the annualized exacerbation rate between the benralizumab 30 mg or 100 mg groups and placebo, under the assumption of a two-sided 4% alpha level test.

[0263] For patients in the primary analysis population with a baseline blood eosinophil count ≥220 / μL, the exacerbation rate in the benralizumab group was compared with placebo using a negative binomial model. The model response variable was the number of exacerbations during the 56-week treatment period. The model included covariates for treatment group, eosinophil count group (220-299 / μL or ≥300 / μL), region, background therapy (ICS / LABA, LABA / LAMA, or ICS / LABA / LAMA), and number of exacerbations in the previous year. Multiple protection for the total type I error rate was accounted for by the Hochberg procedure. In the TERRANOVA, the benralizumab 10 mg treatment group was not subject to multiple protection.

[0264] Secondary efficacy endpoints were analyzed in patients with baseline blood eosinophils ≥220 / μL. Analyses of secondary endpoints were not protected against multiplicity. Changes from baseline in pre-bronchodilator FEV1 at Week 56 were compared between each of the benralizumab dose groups and placebo via repeated measures analysis. Changes from baseline in SGRQ total score at Week 56 were analyzed separately using a similar model. Safety parameters were analyzed by pooled counts during the study.

[0265] For each trial's primary efficacy variable, prespecified subgroup analyses were performed according to patient demographics, respiratory disease characteristics, prior medication use, and prior exacerbations (<3 or ≥3). The studies were not designed or powered to assess efficacy within these subgroups. Therefore, these analyses were considered exploratory.

[0266] Example 2 - Results

[0267] Study Group

[0268] Overall, GALATHEA and TERRANOVA patient characteristics and demographics were similar to those of the primary analysis population with a baseline blood eosinophil count ≥220 / μL (Table 1). Most patients were Caucasian with a mean age of 65 years. Current (non-primary diagnosis) and past asthma rates were low (<7% and ≤10%, respectively, in all study groups) (Table 1). At baseline, most patients (93.0%) were classified as the Global Initiative for COPD (GOLD) D group. The percentage of patients who changed background maintenance therapy during the treatment or post-treatment phase was low (<5% and <1%, respectively). All results reported are for the primary analysis population (GALATHEA, n=1,120; TERRANOVA, n=1,545).

[0269] In GALATHEA and TERRANOVA, >83% and >79% of patients across all treatment groups, respectively, completed treatment. The main reasons for treatment discontinuation were AEs and patient decisions (data not shown).

[0270]

[0271]

[0272] Primary endpoint: In GALATHEA, patients treated with benralizumab experienced a reduction in the annualized rate of COPD exacerbations at Week 56 compared with placebo. The estimated annualized exacerbation rates (95% confidence intervals [CIs]) for benralizumab 30 mg, 100 mg, and placebo were 1.19 (1.04, 1.36), 1.03 (0.90, 1.19), and 1.24 (1.08, 1.42), respectively; the treatment effects of benralizumab 30 mg and 100 mg compared with placebo were 0.96 (P = 0.6490) and 0.83 (P = 0.0525), respectively (Table 2, Figure 2 Benralizumab 100 mg also reduced the annualized rate of severe exacerbations (treatment effect compared with placebo, 0.57 [nominal P = 0.0175]) (Table 2, Figure 2 ).

[0273] In TERRANOVA, patients treated with benralizumab 10 mg or 100 mg had a reduced annualized COPD exacerbation rate compared with placebo at week 56. The estimated annualized exacerbation rates (95% CI) for benralizumab 10 mg, 30 mg, 100 mg, and placebo were 0.99 (0.87, 1.13), 1.21 (1.08, 1.37), 1.09 (0.96, 1.23), and 1.17 (1.04, 1.32), respectively; the treatment effects of benralizumab 10 mg, 30 mg, and 100 mg compared with placebo were 0.85 (P=0.0638), 1.04 (P=0.6575), and 0.93 (P=0.3988), respectively (Table 2). A numerical difference favoring benralizumab was also observed with respect to the reduction in the annualized severe exacerbation rate (treatment effects of 0.75 [nominal P = 0.1478], 0.88 [nominal P = 0.4835], and 0.68 [nominal P = 0.0516] for benralizumab 10 mg, 30 mg, and 100 mg, respectively, compared with placebo) (Table 2, Figure 2 ).

[0274] Key Secondary Outcomes: There were no statistically significant differences in the secondary outcomes for benralizumab compared with placebo at Week 56. In GALATHEA, the change from baseline in pre-bronchodilator FEV1 was 7 mL and 21 mL for benralizumab 30 mg and 100 mg, respectively, compared with placebo. For the SGRQ total score, the treatment effect of benralizumab was -1.011 and -2.136 for benralizumab 30 mg and 100 mg, respectively, compared with placebo (Tables 2 and Figure 3 In TERRANOVA, the changes from baseline in pre-bronchodilator FEV1 were 15 mL, -7 mL, and 20 mL for benralizumab 10 mg, 30 mg, and 100 mg, respectively, compared with placebo. For the SGRQ total score, the treatment effects of benralizumab were -1.011, -1.388, and -0.602 for benralizumab 10 mg, 30 mg, and 100 mg, respectively, compared with placebo (Table 2 and Figure 3 Patients randomized to placebo in GALATHEA and TERRANOVA also had large improvements in SGRQ scores at Week 56 (mean changes from baseline of -3.856 and -6.863, respectively).

[0275]

[0276] In both trials, all benralizumab doses resulted in complete depletion of blood eosinophils from week 4 to the end of the study, compared with no depletion with placebo ( Figure 4In the GALATHEA substudy, benralizumab resulted in almost complete depletion at Week 24 (means of 0.02% and 0.13% for 30 mg and 100 mg, respectively, compared with 5.38% for placebo), which was maintained through Week 56.

[0277] Prespecified Subgroup Analyses: Point estimates of the annualized COPD exacerbation rate ratio (RR) favored benralizumab 100 mg compared with placebo for all demographic subgroups, except for current smokers in GALATHEA, for whom benralizumab and placebo had similar results (point estimate, 1.00). The subgroup of patients with ≥3 prior exacerbations had a greater treatment effect with benralizumab 100 mg compared with <3 prior exacerbations (reductions compared with placebo: GALATHEA, 39% vs. 2%, respectively; TERRANOVA, 23% vs. 2%, respectively) ( Figure 5 and Figure 6 Patients with baseline eosinophil counts ≥ 220 / μL showed a greater reduction in exacerbation rate with benralizumab 100 mg (RR [95% CI] compared with placebo: GALATHEA, 0.83 [0.69, 1.00]; TERRANOVA, 0.93 [0.78, 1.10]) compared with patients with baseline eosinophil counts < 220 / μL (RR [95% CI] compared with placebo: GALATHEA, 1.02 [0.82, 1.27]; TERRANOVA, 1.02 [0.80, 1.30]). There was no trend between increasing eosinophil counts and treatment effect ( Figure 7 ).

[0278] Benralizumab 100 mg produced an increased treatment effect in patients already receiving triple therapy compared with other treatment options (reduction in COPD exacerbation rate compared with placebo: GALATHEA, 18%; TERRANOVA, 17%) ( Figure 5 and Figure 6 In both trials, patients with frequent prior exacerbations (≥3) or very severe GOLD airflow severity responded with a greater benralizumab treatment effect than patients with few prior exacerbations or moderate GOLD airflow severity. The benralizumab treatment effect varied slightly by region (data not shown).

[0279] Safety: In GALATHEA and TERRANOVA, AE types and frequencies were similar between the benralizumab and placebo groups, and mortality was low (Table 3). The most common AEs were related to COPD or respiratory disorders. Less than 15% of patients had positive anti-drug antibody (ADA) reactions (Table 3), which did not appear to affect clinical outcomes.

[0280]

[0281] discuss:

[0282] Although not statistically significant compared to placebo, benralizumab shows evidence of reducing the exacerbation rate as an additional maintenance treatment for patients with moderate to very severe COPD, receiving ICS / LABA, LABA / LAMA or ICS / LABA / LAMA inhalation therapy, with a history of COPD exacerbation, and blood eosinophil counts ≥220 / μL. Subgroup analysis in both studies consistently identified patients with blood eosinophil counts ≥300 eosinophils / μL, with a history of more frequent exacerbations (e.g., ≥3 exacerbations in the previous year) and those receiving triple background therapy (e.g., ICS / LABA / LAMA) as being most likely to respond to benralizumab 100mg treatment. In addition, compared to placebo, the annual severe COPD exacerbation rate was reduced by>30% with benralizumab 100mg.

[0283] Most benralizumab doses were associated with small improvements in lung function from baseline. Benralizumab treatment also improved SGRQ scores, as did placebo. All patients received the study inhaled therapy, which improved the results in the placebo group to varying degrees. This, combined with the strong placebo effect, could potentially have led to benralizumab's failure to achieve statistical significance in improving lung function and other endpoints.

[0284] During these trials, AE / serious AEs were balanced between treatment groups and mortality was low. These safety data are consistent with those reported in Phase III trials of benralizumab for severe, uncontrolled eosinophilic asthma (Bleecker et al., Lancet, 388:2115-2127, 2016; Fitzgerald et al., Lancet, 388:2128-2142, 2016).

[0285] COPD is a complex disease driven by multiple mechanisms, which leads to a wide range of clinical disease manifestations (Singh et al., BRN Review [BRN Review], 4: 34-52, 2018). Biological agents (such as benralizumab) target discrete potential pathological mechanisms (eosinophilic inflammation). As of the 4th week, and until the 56th week, benralizumab caused complete depletion of eosinophils in blood and sputum. This finding, together with the similar effects on eosinophils observed in the mepolizumab trial and the minimal effect on the COPD exacerbation rate, indicates that eosinophil depletion may not completely improve the exacerbation results of patients with COPD. In addition, peripheral blood eosinophil counts may not accurately reflect airway eosinophilia. The clinical characteristics of COPD are another key factor. Both GALATHEA and TERRANOVA indicate that patients with more frequent COPD exacerbations in the year before enrollment still experience the greatest benralizumab treatment effect despite receiving triple inhalation therapy. We believe this is an important finding because both variables are easily identified and, together with blood eosinophil counts, could help personalize the treatment of COPD patients with benralizumab.

[0286] Example 3 - Another Phase 3 Study

[0287] This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter, Phase 3 study to evaluate the efficacy and safety of benralizumab 100mg doses administered by subcutaneous (SC) injection in patients with moderate to very severe COPD, with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300 / μL), with the first three doses administered every 4 weeks and then every 8 weeks (hereinafter referred to as Q8W). Eligible patients must have a history of ≥2 moderate and / or severe COPD exacerbations in the previous year despite receiving triple (ICS / LABA / LAMA) background therapy. Eligible patients must also have an elevated blood eosinophil count of ≥300 / μL at screening, supported by historical results of at least 1 ≥150 / μL in the previous year.

[0288] In the previous Phase 3 studies GALATHEA and TERRANOVA, long-term treatment with benralizumab 10, 30, or 100 mg Q8W through Week 48 was well tolerated in patients with moderate to very severe COPD. There were no clear differences in safety outcomes among the 3 dose groups.

[0289] Results from both studies provided consistent and clear evidence that the benralizumab 100 mg dose had a greater treatment effect than the 30 mg dose in reducing the annualized COPD exacerbation rate (moderate and severe combined) and the annualized severe exacerbation rate, as well as all other exacerbation endpoints, in patients with a baseline blood eosinophil count ≥220 / μL. In the exacerbation endpoint, the benralizumab 10 mg dose (TERRANOVA only) provided inconsistent results compared with the 100 mg dose. However, for severe exacerbations, a greater treatment effect was observed with the benralizumab 100 mg dose compared with the 10 mg dose in patients with a baseline blood eosinophil count ≥220 / μL (32% and 25% reduction, respectively, compared with placebo). In patients with more frequent prior exacerbations (≥3 exacerbations in the previous year) and baseline blood eosinophil counts ≥220 / μL, a significantly greater treatment effect of benralizumab 100 mg than the 10 mg dose was evident for COPD exacerbations (moderate and severe combined; 23% vs. 9% reduction, respectively, compared with placebo) and for severe exacerbations (34% vs. 17% reduction, compared with placebo). In general, any improvements observed in patients treated with benralizumab were greater in the 100 mg group compared with the 30 mg group. In both studies, benralizumab 100 mg reduced the annual severe exacerbation rate by >30% compared with placebo. However, in GALATHEA, patients receiving benralizumab 30 mg had a greater severe exacerbation rate compared with placebo. These results suggest that patients with COPD may require larger doses of benralizumab to achieve a therapeutic response compared with patients with asthma, for whom benralizumab 30 mg is sufficient to achieve a therapeutic effect on asthma. The benralizumab 100 mg dose was selected for this study given the more consistent efficacy findings, particularly in subpopulations with more frequent exacerbations and elevated eosinophils (≥220 / μL).

[0290] Potentially eligible patients will enter a 5-week run-in period. Patients meeting the eligibility criteria will be randomized in a 1:1 ratio to receive benralizumab 100 mg or placebo Q8W. The treatment period will be of variable duration and will continue until the last patient has the opportunity to complete at least 56 weeks, at which point all patients will have completed the study. The primary endpoint will be analyzed at Week 56.

[0291] At randomization, patients will be stratified by country and number of exacerbations in the previous year (2 or ≥3). The stratum randomized to 2 exacerbations in the previous year will be capped to ensure that ≥70% of patients in the study population have ≥3 exacerbations in the previous year.

[0292] Patients will be maintained on triple (ICS / LABA / LAMA) background therapy from enrollment and throughout the run-in and treatment periods.

[0293] Number of patients:

[0294] In the study, a total of 868 patients are expected to be randomized in a 1:1 ratio to either benralizumab 100 mg SC or matching placebo treatment groups.

[0295] Treatment and duration of treatment:

[0296] Once enrolled, patients will enter a run-in period, which will last a minimum of 5 weeks and can be extended up to 13 weeks. Following the run-in period, eligible patients will be randomized in a 1:1 ratio to receive either benralizumab 100 mg or placebo SC Q8W. The treatment period will be of variable duration and will continue until the last patient has had the opportunity to complete a minimum of 56 weeks. When the last patient's end-of-treatment (EOT) visit is determined, a final visit will be scheduled for all patients. The study will end when all patients have completed their final visit.

[0297] Statistical methods

[0298] Efficacy analyses will be performed using the full analysis set (FAS), which will include all randomized patients who received at least 1 IP dose according to the intention-to-treat principle, regardless of their protocol compliance and continued participation in the study.

[0299] The primary efficacy endpoint was the annualized moderate and severe COPD exacerbation rate during the first 56 weeks. Treatment strategy estimates were applied to the primary analysis of the primary endpoint (and to the primary analysis of key secondary endpoints) to include all data regardless of whether patients remained on blinded IP.

[0300] The primary endpoint will be assessed first in the primary population (patients with ≥3 exacerbations in the previous year) and then in the total population of patients with ≥2 exacerbations in the previous year. The exacerbation rate in the benralizumab 100 mg group will be compared with the exacerbation rate in the placebo group using a negative binomial model. The response variable in the model will be the number of COPD exacerbations during the first 56 weeks of the treatment period. The model will include covariates for treatment group, region, and number of exacerbations in the previous year. The logarithm of the follow-up time during the first 56 weeks will be used as a displacement variable in the model. Hypothesis testing for the primary analysis will be performed at a bilateral 5% significance level.

[0301] The annualized rate of COPD exacerbations leading to hospitalization or death (ie, severe exacerbations) until EOT will be analyzed using a negative binomial model similar to that outlined for the primary efficacy variable.

[0302] Unless otherwise documented, all secondary efficacy endpoints will be analyzed in patients with a history of ≥3 exacerbations in the previous year using data through Week 56, and repeated in patients with a history of ≥2 exacerbations in the previous year. Where continuously measured endpoints (e.g., SGRQ and FEV1) are also collected beyond Week 56, these endpoints will be assessed until EOT using additional models similar to those fitted to the data through Week 56.

[0303] The study will recruit patients on triple (ICS / LABA / LAMA) background therapy with a baseline eosinophil count ≥300 eosinophils / μL and ≥2 exacerbations in the previous year, of which at least 70% of patients have ≥3 exacerbations in the previous year. The study is available for the main population with ≥3 exacerbations in the previous year. For the primary endpoint of annualized exacerbation rate during the first 56 weeks, a minimum of 304 patients / group with ≥3 exacerbations in the previous year (608 total) will be randomized to obtain at least 90% power to detect a 30% reduction in benralizumab 100 mg compared to placebo. This calculation assumes a bilateral 5% alpha level, an annual placebo rate of 2, and a negative binomial dispersion parameter of 0.5.

[0304] A total of 868 patients are expected to be randomized in the study, also including a cohort of patients with 2 exacerbations in the previous year (approximately 260 patients) to characterize efficacy in patients with ≥2 exacerbations in the previous year.

[0305] The overall study design is outlined in Fig.11 middle.

[0306] Based on the discovery identification study population from GALATHEA and TERRANOVA, the GALATHEA and TERRANOVA are Phase 3 studies of benralizumab in patients with moderate to very severe COPD. Two Phase 3 studies have almost the same research design and include patients who are within a certain baseline blood eosinophil range, despite dual or triple background therapy of ICS / LABA, LAMA / LABA or ICS / LAMA / LABA, but still have a history of exacerbation. The main population is patients with baseline eosinophil counts ≥220 / μL in GALATHEA and TERRANOVA. In this new study, the main population is patients with baseline eosinophil counts ≥300 eosinophils / μL, who are undergoing triple background therapy (ICS / LABA / LAMA), and have ≥3 exacerbations in the previous year. The total population was patients with a baseline eosinophil count ≥300 eosinophils / μL who were on triple background therapy (ICS / LABA / LAMA) and had ≥2 exacerbations in the previous year.

[0307] In the primary analyses of GALATHEA and TERRANOVA, the benralizumab 100 mg dose resulted in a 17% and 7% reduction in the primary endpoint of annualized COPD exacerbation rate (moderate and severe combined) compared with placebo in GALATHEA and TERRANOVA, respectively. However, clinically relevant reductions in severe exacerbations (defined as exacerbations leading to hospitalization or death) were observed in both studies, with the greatest effect observed in the benralizumab 100 mg group (43% and 32% in GALATHEA and TERRANOVA, respectively).

[0308] Preplanned analyses evaluated specific subpopulations and yielded the following results:

[0309] - In both studies, patients on background triple (ICS / LABA / LAMA) therapy (approximately 70% and 60% of patients in GALATHEA and TERRANOVA, respectively) had consistent treatment effects on the annualized COPD exacerbation rate with benralizumab 100 mg: 18% and 17% reductions, respectively, compared to placebo.

[0310] - With benralizumab 100 mg, patients with more frequent exacerbations in the previous year (≥3 versus ≤2) had greater treatment effects on annualized COPD exacerbation rate and annualized severe exacerbation rate.

[0311] -No treatment effect on the annualized COPD exacerbation rate was observed in patients with baseline blood eosinophils <220 / μL.

[0312] Findings in these subgroups were consistent across studies and supported by pooled analyses. Taken together, these characteristics identify those patients most likely to benefit from benralizumab treatment.

[0313] An eosinophil cut-off of ≥300 / μL was used for this study. In previous GALATHEA and TERRANOVA studies, efficacy was not seen in patients with low eosinophil counts (<220 / μL). Treatment responses were similar between patients with ≥220 / μL versus ≥300 / μL. GOLD 2019 mentions a threshold of 300 / μL in terms of response to ICS, and the 300 / μL cut-off is more practical from a clinical perspective and consistent with clinical laboratory blood count data decomposition.

[0314] In GALATHEA and TERRANOVA, a history of frequent exacerbations (≥3 times) in the previous year was the strongest and most consistent predictor of treatment response. Therefore, this study will be able to be used for the main patient population with ≥3 exacerbations in the previous year. Considering that there is evidence in the GALATHEA and TERRANOVA studies that there is a therapeutic effect in this subgroup of patients with a baseline blood eosinophil count of ≥220 / μL who are undergoing triple (ICS / LABA / LAMA) background therapy, the expansion study was enrolled to additionally include patients with 2 exacerbations in the previous year to allow for further exploration in a wider population (patients with ≥2 exacerbations in the previous year). In a post hoc analysis of the summary in this population (blood eosinophils ≥220 / μL, ≥2 exacerbations in the previous year, and triple therapy being performed), benralizumab 100mg resulted in a 20% reduction in the annual exacerbation rate compared to placebo, and a 55% reduction in the annual severe exacerbation rate compared to placebo.

[0315] The study will include chest CT imaging to provide needed information related to exclusion criterion 3 and to evaluate the potential impact of structural lung disease on efficacy.

[0316] Inclusion Criteria

[0317] - Patients (male or female) must be between 40 and 85 years of age (inclusive) at the time of signing the ICF.

[0318] - Current smoker or former smoker with ≥10 pack-years of smoking history (1 pack-year = 20 cigarettes per day for 1 year). (Note: The pack-year count in the eligibility criteria does not include electronic cigarette [e-cigarette] use.)

[0319] - History of moderate to very severe COPD with post-bronchodilator FEV1 / forced vital capacity (FVC) < 0.70 and post-bronchodilator FEV1 ≤ 65% of predicted normal on screening central spirometry assessment.

[0320] - Documented history of 2 or more moderate and / or severe COPD exacerbations requiring treatment with systemic corticosteroids (at least 3 days or a single injection of a depot formulation) and / or hospitalization within 52 weeks prior to enrollment:

[0321] (a) It is considered that exacerbations treated with antibiotics alone do not qualify

[0322] Standard unless concomitantly treated with systemic corticosteroids and / or hospitalization.

[0323] (b) Hospitalization was defined as an inpatient admission for ≥24 hours in a hospital, observation area, emergency department, or other equivalent health care facility (depending on the country and healthcare system).

[0324] (c) It should be confirmed that the previous exacerbation occurred while the patient was on stable triple (ICS / LABA / LAMA) background therapy for COPD and not due to a step-down in therapy (i.e., from triple to dual therapy).

[0325] - Documented use of triple (ICS / LABA / LAMA) background therapy for COPD throughout the year (52 weeks) prior to enrollment.

[0326] (a) ICS dose should be equivalent to ≥ 500 mcg of fluticasone propionate per day.

[0327] (b) Patients may switch therapy and / or downgrade therapy for short periods of time during the previous year, but the total cumulative duration that the patient is off triple (ICS / LABA / LAMA) background therapy must not exceed 2 months.

[0328] (c) Patients must have been on stable therapy / dose for the last 3 months prior to randomization. (Individual component changes or switches between devices were permitted as long as the patient continued on an acceptable ICS dose equivalent to ≥500 mcg of fluticasone propionate per day.)

[0329] - Blood eosinophil count ≥300 / μL at the time of screening central laboratory testing, supported by at least 1 documented historical eosinophil count ≥150 / μL within 52 weeks of enrollment. In the absence of historical data, additional blood eosinophil counts may be obtained by repeat testing (at least 4 weeks apart) during the run-in period.

[0330] - CAT total score ≥15 at Visit 1.

[0331] - An exacerbation will be considered moderate if it requires treatment with systemic steroids and does not result in hospitalization. An exacerbation will be considered severe if it results in hospitalization.

[0332] Exclusion criteria

[0333] 1Clinically important lung disease other than COPD (e.g., active lung infection, clinically significant bronchiectasis, pulmonary fibrosis, cystic fibrosis, obesity-related hypoventilation syndrome, lung cancer, alpha-1 antitrypsin deficiency, and primary ciliary dyskinesia).

[0334] 2 Current diagnosis of asthma, past history of asthma, or asthma-COPD overlap according to the Global Initiative for Asthma (GINA) or other accepted guidelines.

[0335] 3. Radiologic findings suggestive of respiratory disease other than COPD that contributes to the patient's respiratory symptoms. Radiologic findings of a solitary pulmonary nodule without adequate follow-up and demonstration of stability consistent with standard of care, or findings suggestive of acute infection.

[0336] 4 Another diagnosed pulmonary or systemic disease associated with an elevated peripheral eosinophil count (e.g., allergic bronchopulmonary aspergillosis / fungal disease,

[0337] Eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome).

[0338] Study treatment was defined as any investigational product (including commercially available comparator products and placebo) or medical device intended to be administered to patients according to the study protocol. Study treatment in this study was either benralizumab or placebo.

[0339] Combination therapy

[0340] - All background COPD medications (e.g. ICS / LABA / LAMA, long-term antibiotics, etc.) and treatments given for COPD exacerbations in the 12 months prior to enrollment.

[0341] - All other medications taken for any reason within 3 months prior to enrollment

[0342] - Concomitant treatment given for therapeutic reasons during the study period (at each study visit)

[0343] COPD medications taken at the time of historical exacerbations were captured in the eCRF, including any recent changes in the timing of these medications relative to the exacerbations.

[0344] Patients should continue their usual triple (ICS / LABA / LAMA) background therapy formulation, dose, and schedule throughout the enrollment, run-in, and treatment periods, as well as any additional permitted COPD medications they may have been taking prior to enrollment.

[0345] Background (maintenance) medications

[0346] All patients were required to be treated with triple (ICS / LABA / LAMA) background therapy for COPD throughout the year prior to enrollment and during the study. Patients must have been on stable ICS / LABA / LAMA therapy / dose with an acceptable ICS dose equivalent to ≥500 mcg fluticasone propionate per day for the last 3 months prior to randomization.

[0347] The purpose of this study is to establish the therapeutic effect of benralizumab as an add-on to triple therapy. Therefore, background medications should be maintained at the same dose and schedule from enrollment until the end of the study.

[0348] Minor changes in the formulation of a patient's background inhaled medications were permitted, such as changes in individual components (e.g., fluticasone to equivalent doses of budesonide) or switches between devices (e.g., budesonide / formoterol to fluticasone / salmeterol), as long as the patient continued on ICS / LABA / LAMA at an acceptable ICS dose. In the case of such minor changes, patients should have been stable on the new treatment regimen for at least 4 weeks prior to randomization.

[0349] Emergency medicine

[0350] In the event of an exacerbation of COPD symptoms during the study period, short-acting β2 agonists (SABAs, e.g., salbutamol, salbutamol, terbutaline, levalbuterol), short-acting muscarinic antagonists (SAMAs), SABA / SAMA combinations, or alternative rescue medications consistent with local standard of care were available.

[0351] Table 4 provides a list of permitted, restricted, and prohibited drugs.

[0352] Table 4.

[0353]

[0354]

[0355] Example 4 - Research Assessment and Procedures

[0356] Evaluation of COPD exacerbation:

[0357] For protocol purposes, a COPD exacerbation is defined as an increase in a patient's usual COPD symptoms that is beyond the normal daily variation, is acute at onset, lasts for 2 or more days (or a single day if the exacerbation is so rapid and significant that intensification of treatment cannot be delayed in the judgment of the treating physician), and may require a change in usual medication therapy and result in any of the following:

[0358] Use systemic corticosteroids for at least 3 days; a single depot injection dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids;

[0359] -Use of antibiotics

[0360] - Inpatient hospitalization due to COPD (defined as an inpatient admission for ≥24 hours in a hospital, observation area, emergency department, or other equivalent health care facility (depending on the country and healthcare system)

[0361] - Causes death

[0362] An exacerbation / attack must include at least 1 major COPD symptom and at least one other major or minor symptom from the following:

[0363] -Main COPD symptoms: dyspnea, sputum volume and color

[0364] -Minor COPD symptoms: cough, wheezing, sore throat, cold symptoms (rhinorrhoea or nasal congestion), and fever without other causes

[0365] An exacerbation was considered moderate if it required treatment with systemic steroids and / or antibiotics and did not result in hospitalization or death. An exacerbation was considered severe if it resulted in hospitalization or death.

[0366] Spirometry

[0367] Patients should be instructed not to take their ICS / LABA / LAMA medications within 12 hours (24 hours for once-daily medications) of a scheduled on-site visit spirometry because this will affect pre / post-bronchodilator FEV1 values; patients can then take their medications on-site. For the same reason, patients should not take their rescue (SABA and / or SAMA) medications within 6 hours of a scheduled on-site visit spirometry.

[0368] For each on-site spirometry session, multiple forced expiratory efforts (at least 3, but no more than 8) will be performed. Spirometry grading will meet the ATS / ERS acceptability and reproducibility criteria as detailed in the Spirometry Manual. The highest FEV1 and FVC will be based on the maximal effort that meets the acceptability criteria. The highest FEV1 and FVC recorded do not need to be from the same effort and can be derived from separate efforts. Absolute measurements (for FEV1 and FVC) and percentages of predicted normal values ​​will be recorded (Quanjer et al. 2012).

[0369] Postbronchodilator spirometry

[0370] Maximal bronchodilation will be induced with 4 inhalations of albuterol (90 μg metered dose) or salbutamol (100 μg metered dose) with or without a spacer device within 30 ± 15 minutes of the last pre-bronchodilator spirometry measurement. Post-bronchodilator spirometry will be performed 20 to 30 minutes later. If the patient cannot tolerate 4 puffs of a beta-agonist, a lower number of inhalations may be considered based on the investigator's clinical judgment.

[0371] Patient-Reported Outcomes

[0372] - Daily: EXACT-PRO / E-RS: COPD (first 56 weeks only), background medication use, rescue medication use, and symptom severity questionnaire

[0373] -Every 4 weeks for the first 56 weeks and every 8 weeks thereafter: SGRQ, CAT, and EQ-5D-5L

[0374] -One week after each scheduled visit for IP administration: Onset of Effect Questionnaire (OEQ) - Question 2 (first 56 weeks only)

[0375] St. George's Respiratory Questionnaire (SGRQ)

[0376] The SGRQ is a 50-item PRO tool developed to measure the health status of patients with obstructive airway disease (Jones et al. 1991). The questionnaire is divided into two parts: Part 1 consists of 8 items about the severity of respiratory symptoms in the previous 4 weeks; Part 2 consists of 42 items related to the daily activity and psychosocial impact of the individual's respiratory condition. The SGRQ produces a total score and 3 domain scores (symptoms, activity, and impact). The total score indicates the impact of the disease on overall health status. This total score is expressed as a percentage of total impairment, with 100 indicating the worst possible health status and 0 indicating the best possible health status. Similarly, domain scores range from 0 to 100, with higher scores indicating greater impairment. Specific details of the scoring algorithm are provided by the developer in the user manual (Jones 2009).

[0377] Patients will complete the SGRQ in eDiary on-site at Visit 1 (Screening) and Visit 3 (Randomization) prior to other study procedures. During the Run-in Period and until Week 56 of the Treatment Period, the SGRQ will be available for completion every 28±7 days, preferably at home before study visits or on-site during scheduled visits. After Week 56, the SGRQ will be available for completion every 56±7 days, preferably at home before study visits or on-site during scheduled visits.

[0378] COPD Assessment Test (CAT)

[0379] CAT is an 8-item PRO (Jones et al. 2009) developed to measure the impact of COPD on health status. The tool uses a semantically distinct 6-point response scale, which is defined by contrasting adjectives to capture the impact of COPD. The content includes projects related to cough, sticky sputum, chest tightness, shortness of breath climbing / stairs, limited activities at home, confidence leaving home, sleep, and energy. The CAT total score is the sum of the project answers. The score is in the range of 0 to 40, where higher scores indicate that COPD has a greater impact on health status.

[0380] Patients will complete the CAT on-site at Visit 1 (Screening) and Visit 3 (Randomization) prior to other study procedures. During the Run-in Period and until Week 56 of the Treatment Period, the CAT will be available for completion every 28±7 days, preferably at home prior to study visits or on-site during scheduled visits. After Week 56, the CAT will be available for completion every 56±7 days, preferably at home prior to study visits or on-site during scheduled visits.

[0381] European Quality of Life - 5 Dimensions (EQ-5D-5L)

[0382] The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension has 5 response options (no problem, slight problem, moderate problem, severe problem, and extreme problem) that reflect increasing levels of difficulty.

[0383] Patients will be asked to indicate his / her current health status by selecting the most appropriate level in each of the 5 dimensions. The questionnaire also includes a visual analog scale (VAS), in which patients will be asked to rate their current health status on a scale of 0 to 100, with 0 being the worst health status imaginable. Patients will complete the EQ-5D-5L in eDiary at the site of Visit 1 (screening) and Visit 3 (randomization) before other study procedures. During the lead-in period and until the 56th week of the treatment period, the EQ-5D-5L will be available for completion every 28±7 days, preferably at home before the study visit or on site during the planned visit. After the 56th week, the EQ-5D-5L will be available for completion every 56±7 days, preferably at home before the study visit or on site during the planned visit.

[0384] Statistical considerations

[0385] The primary efficacy endpoint is the annualized moderate and severe COPD exacerbation rate during the first 56 weeks. The primary endpoint will be assessed first in the primary population (patients with ≥3 exacerbations in the previous year) and then in the total population of patients with ≥2 exacerbations in the previous year. The treatment strategy estimate will be applied to the primary analysis of the primary endpoint, thereby including all data, regardless of whether the patient remains blinded IP.

[0386] The null hypothesis is that the exacerbation rate of benralizumab 100 mg is equal to the exacerbation rate of placebo. The alternative hypothesis is that the exacerbation rate of benralizumab 100 mg is not equal to the exacerbation rate of placebo, that is:

[0387] H0: Rate ratio (benralizumab 100 mg vs. placebo) = 1

[0388] H1: Rate ratio (benralizumab 100 mg vs. placebo) ≠ 1

[0389] Hypothesis testing for the primary analysis (annualized moderate and severe COPD exacerbation rate over 56 weeks in patients with ≥3 exacerbations in the previous year) will be performed at a two-sided 5% significance level. If the p-value is less than 0.05 and the treatment effect favors benralizumab, H0 is rejected and H1 is accepted.

[0390] Sample size determination

[0391] The study will recruit patients with a baseline eosinophil count ≥300 / μL and ≥2 exacerbations in the previous year on triple (ICS / LABA / LAMA) background therapy, of which at least 70% of patients have ≥3 exacerbations in the previous year. The study can be used for the main population with ≥3 exacerbations in the previous year. For the primary endpoint of annualized exacerbation rate during the first 56 weeks, a minimum of 304 patients / group with ≥3 exacerbations in the previous year (608 in total) will be randomized to obtain at least 90% power to detect a 30% reduction in benralizumab 100mg compared to placebo. This calculation assumes a bilateral 5% alpha level, an annual placebo rate of 2, and a negative binomial dispersion parameter of 0.5.

[0392] A total of 868 patients are expected to be randomized in the study, also including a cohort of patients with 2 exacerbations in the previous year to characterize efficacy in patients with ≥2 exacerbations in the previous year.

[0393] For the key secondary endpoint of annualized severe exacerbation rate throughout the treatment period to EOT, at least 80% power was expected to detect a 40% reduction with benralizumab 100 mg compared with placebo in patients with ≥3 exacerbations in the previous year, and at least 90% power in patients with ≥2 exacerbations in the previous year. This calculation assumed placebo rates of 0.30 and 0.27 for the primary and total populations, respectively, a negative binomial dispersion parameter of 2.7, and a mean follow-up of 2 years. A two-sided 5% significance level was assumed in the >3 and >2 prior exacerbation groups after a multiple testing procedure.

[0394] Efficacy endpoints

[0395] All efficacy endpoints (listed in Table 5) will be analyzed in patients with a history of ≥3 exacerbations in the previous year (primary population) and repeated in patients with a history of ≥2 exacerbations in the previous year (total population). Where continuously measured endpoints (e.g., SGRQ and FEV1) are also collected beyond Week 56, additional models similar to those fitted to the data up to Week 56 will be used to assess these endpoints during the longer follow-up period to EOT.

[0396] Table 5. Efficacy endpoints

[0397]

[0398]

[0399] Main analytical methods

[0400] The primary efficacy variable was the annualized moderate and severe COPD exacerbation rate during the first 56 weeks, and the primary analysis was the comparison of the annualized COPD exacerbation rate with benralizumab 100 mg versus placebo in patients with a history of ≥3 exacerbations in the previous year.

[0401] The exacerbation rate in the benralizumab treatment group will be compared with the exacerbation rate in the placebo group using a negative binomial model. The response variable in the model will be the number of COPD exacerbations during the first 56 weeks of the treatment period. The model will include covariates for treatment group, region, and number of exacerbations in the previous year. The logarithm of the follow-up time during the first 56 weeks will be used as a displacement variable in the model.

[0402] The estimated treatment effect (ie, rate ratio of benralizumab to placebo), the corresponding 95% confidence interval (CI), and the two-sided p-value for the rate ratio will be presented. In addition, the exacerbation rate and the corresponding 95% CI for each treatment group will be presented.

[0403] Analytical Methods for Secondary Efficacy Variables

[0404] The primary analysis will be repeated in patients with a history of ≥2 exacerbations in the previous year. All secondary efficacy endpoints will be analyzed in patients with a history of ≥3 exacerbations in the previous year and repeated in patients with a history of ≥2 exacerbations in the previous year. In the case where continuous measurement endpoints (e.g., SGRQ and FEV1) are also collected beyond Week 56, other models similar to those fitted to the data until Week 56 will be used to evaluate these endpoints during the longer follow-up period to EOT.

[0405] Until EOT, annualized COPD exacerbation rates leading to hospitalization or death (ie, severe exacerbations) will be analyzed using a similar negative binomial model as outlined above. Until EOT, annualized COPD exacerbation rates associated with emergency room visits or hospitalizations will be analyzed in a similar manner.

[0406] The proportion of patients with ≥1 COPD exacerbation was addressed as a supporting variable for the primary objective. This proportion in the benralizumab group was compared with that in the placebo group using a logistic regression model with region and number of exacerbations in the previous year as covariates.

[0407] Time to first COPD exacerbation was analyzed as an additional efficacy variable supporting the primary objective to explore the extent to which benralizumab treatment delayed the time to first exacerbation compared with placebo. A Cox proportional hazards model was fit to the data with covariates for treatment, region, and number of exacerbations in the previous year.

[0408] The change from baseline in the SGRQ total score and three domain scores (symptoms, activity, and impact) at Week 56 will be compared between benralizumab and placebo using repeated measures analysis in the FAS. The dependent variable will be the change from baseline in the SGRQ score at the post-baseline protocol-specified visits (up to the Week 56 visit). Treatment group will be fitted as an explanatory variable, and region, visit, the interaction between visit and treatment, and baseline SGRQ score will be fitted as covariates. Visit will be fitted as a categorical variable, and the variance-covariance matrix will be assumed in the following order: unstructured, Toeplitz, first-order autoregressive, compound symmetry, and variance components. If the procedure does not converge, the next covariance matrix will be used. The model is:

[0409] Change in SGRQ score = treatment group + baseline SGRQ score + region + visit + treatment * visit

[0410] The proportion of patients in the benralizumab group who had a ≥4-point reduction (improvement) in the SGRQ total score at Week 56 was compared with that in the placebo group using the Cochran-Mantel-Haenszel test controlled for region.

[0411] The change from baseline in Predose / prebronchodilator FEV1 at Week 56 will be analyzed in patients with baseline Predose / prebronchodilator FEV1 and at least one post-randomization Predose / prebronchodilator FEV1 using a repeated measures analysis model similar to that for the change from baseline in SGRQ scores.

[0412] Change from baseline in CAT total score at week 56 and E-RS: COPD total and domain scores at week 56 will be analyzed separately using models similar to those for change from baseline in SGRQ scores.

[0413] ***

[0414] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific aspects of the disclosure described herein. Such equivalents are intended to be encompassed by the following claims.

[0415] Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

[0416] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.

[0417]

[0418]

Claims

1. A method of treating chronic obstructive pulmonary disease (COPD) in a human COPD patient, the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient: (a) blood eosinophil count ≥300 eosinophils / μL; (b) experienced ≥2 prior exacerbations in the year prior to administration; and (c) On triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

2. A method for reducing the annual exacerbation rate of chronic obstructive pulmonary disease (COPD), the method comprising administering a 100 mg dose of benralizumab or an antigen-binding fragment thereof to a human COPD patient, wherein prior to administration, the patient: (a) blood eosinophil count ≥300 eosinophils / μL; (b) experienced ≥2 prior exacerbations in the year prior to administration; and (c) On triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

3. A method for increasing the forced expiratory volume in one second (FEV1) in human patients with chronic obstructive pulmonary disease (COPD) 1 ), the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient: (a) blood eosinophil count ≥300 eosinophils / μL; (b) experienced ≥2 prior exacerbations in the year prior to administration; and (c) On triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

4. A method of increasing forced vital capacity (FVC) in a human chronic obstructive pulmonary disease (COPD) patient, the method comprising administering to the patient a 100 mg dose of benralizumab or an antigen-binding fragment thereof, wherein prior to administration, the patient: (a) blood eosinophil count ≥300 eosinophils / μL; (b) experienced ≥2 prior exacerbations in the year prior to administration; and (c) On triple background therapy including an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA).

5. The method of any one of claims 1-4, wherein a COPD questionnaire score assessing COPD symptoms in the human COPD patient is improved.

6. The method of any one of 1-5, wherein the patient suffers from severe or very severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

7. The method of claim 6, wherein the patient suffers from very severe COPD as defined by GOLD.

8. The method of any one of claims 1-7, wherein the administration reduces the exacerbation rate of COPD.

9. The method of any one of claims 2-8, wherein the deterioration rate is reduced by at least 20%.

10. The method of any one of claims 2-8, wherein the deterioration rate is reduced by at least 30%.